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Abstract
This thesis examines the role played by CD4+ and CD8+ T cells in the rejection 
of a class I disparate cardiac allograft in a rat model (R8—RT1U). The effector 
mechanisms involved in the rejection process are studied, and particular emphasis 
given to the possibility of specific alloantibody acting as an effector of acute 
allograft rejection.
Following the establishment of the rejection times of a class I disparate, 
heterotopic, intra-abdominal, cardiac allograft in unmodified animals, 
manipulation of T cell subsets in the recipient animals was achieved in vivo by the 
administration of mouse anti-rat monoclonal antibodies specific for either the 
CD4 or the CD8 molecule. Depletion of CD8+ T cells had no effect on graft 
survival whereas CD4+ T cell depletion resulted in prolonged allograft survival. 
In addition, the acceptance of the class I disparate graft following anti-CD4 
monoclonal antibody treatment was associated with the abrogation of the specific 
alloantibody response against the donor tissue seen in unmodified rejection and in 
the anti-CD8 treated group.
Anti-class I alloantibody was shown to specifically lyse in vitro cultures of donor 
cardiac endothelial cells and passive transfer of immune serum in vivo results in 
the restoration of acute rejection in an animal depleted of CD4+ T cells.
This calls into question the accepted belief that the CD8+ T cell is of crucial 
importance in the acute rejection of a class I disparate allograft, by its role as a 
cytotoxic T cell. The CD8+ T cell is not required for the rejection of such a graft 
in this model. On the contrary, the CD4+ T cell was found to be essential to the 
rejection process and the findings of the alloantibody experiments suggest that the 
CD4+ T cell is mediating acute rejection by providing T cell help for the 
production of specific, cytotoxic alloantibody.
The significant finding of the rejection of a class I disparate allograft in the 
absence of CD8+ T cells provides further support for the indirect pathway of 
allorecognition.
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CHAPTER ONE
INTRODUCTION
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1:1 Historical aspects of transplantation.
Transplantation of viable tissue and organs from one person to another has 
been introduced and developed as a therapeutic tool during the Twentieth century.
The first human cadaveric renal transplant was carried out in 1933 by the 
Russian surgeon Voronoy. The recipient was in acute renal failure as a result of 
mercury poisoning. The donor had died following a severe head injury and there 
was a six hour warm ischaemic time before transplantation. Although the 
operation was a technical success, the kidney never functioned, did not reverse 
the patients condition and he died soon after the operation (Voronoy, 1936). In the 
early 1950's the first technically and therapeutically successful renal transplant 
was performed in Boston, U.S.A., between identical twins, thereby avoiding the 
insurmountable problem of graft rejection. Other renal transplants, performed in 
this centre, between donors and recipients who were not identical twins, all failed 
rapidly as a result of graft rejection by the recipient (Hume, Merril, Miller et al, 
1955).
It was not until the early 1960's that it was discovered that treating 
transplant recipients with Azathioprine resulted in a highly significant reduction 
of rejection episodes (Caine, Alexander & Murray, 1962). This important 
breakthrough led to the increased use of renal transplantation as treatment for end- 
stage renal failure. The advances in treatment and control of graft rejection 
encouraged the development of techniques to transplant other organs and, in 1967, 
Barnard performed the first successful heart transplant in South Africa (Barnard, 
1967). This success was repeated in centres in North America, particularly by
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Shumway in Stanford who developed the technique used by Barnard, and the 
operation of cardiac transplantation has now become commonplace, throughout 
the world, in the treatment of various cardiac conditions such as ischaemic heart 
disease and cardiomyopathies (Yacoub et al, 1987).
Similarly, liver transplantation has been pioneered and developed in the 
latter part of this century, most notably by Professor Starzl in Pittsburgh U.S.A. 
(Starzl et al, 1963), and Professor Caine in Cambridge, U.K., and is now widely 
performed as treatment in cases of fulminant hepatic failure, of various aetiologies 
(Caine et al, 1981; Starzl et al, 1982; Starzl et al, 1985).
Other organs and tissues which are currently being transplanted, or are the 
subject of intensive research to assess their suitability for transplantation, include: 
Lung (double or single); Pancreas (whole organ or islets); Small bowel; Large 
bowel; Cornea and Bone (Green, 1988). In addition there is increasing interest in 
the possibility of using xenografts, in certain clinical applications, although the 
use of other animal species in transplantation into human recipients raises 
important ethical issues which will need to be addressed before such procedures 
gain widespread acceptance. Research into this area of transplantation is rapidly 
gaining momentum.
The primary problem which has had to be addressed to allow these 
advances in organ transplantation to be made is how to overcome, and control, the 
immune response with which the recipient of an allogeneic transplant attempts to 
destroy the graft, which is foreign to them.
Following on from the pioneering work of Caine in introducing 
azathioprine perhaps the greatest step forward in transplantation (other than the 
development of the operative techniques) was the introduction of Cyclosporin A 
(CyA) into clinical use in the late 1970's (Caine et al, 1978). This drug, which is a
i
!
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metabolite derived from a fungus (Tolypocladium inflatum Gams), initially found 
in soil samples by the Department of Microbiology at Sandoz in Basle as an anti- 
fungal agent of limited activity (Dreyfuss, Harri, Hotmann et al, 1976), was 
subsequently shown to be an exquisitely potent immunosuppressive agent, both 
in vitro and in vivo, which blocked the activation of T cells at concentrations 
which were not toxic to other cell types (Borel, Feurer, Magnee et al, 1977). Its 
use, alone or in combination with more established drugs like Azathioprine and 
steroids, has allowed one year survival rates for renal transplants to climb as high 
as 85-90%. The main advantage of cyclosporin is that, unlike azathioprine, it is 
not an anti-metabolite but is specifically effective against T cells and does not 
prevent the normal proliferation of other cell types
Most recently, FK506, a macrolide antibiotic which differs considerably in 
structure to CyA, has been introduced and early work has suggested that it shows 
great promise in salvaging, and/or preventing rejection of liver grafts (Starzl et al, 
1991). Both CyA and FK506 act largely by inhibiting production of the cytokine, 
interleukin-2 (IL-2), which is produced by helper T cells during the rejection 
response, and which recruits and activates cellular components of the rejection 
response. Both drugs act at a step distal to the cell membrane receptors but 
proximal to late signalling events such as the transcription activation of early 
genes. They bind endogenous intracellular receptors, the immunophilins, and the 
resulting complex targets the protein phosphatase, calcineurin, to exert the 
immunosuppressive effect by preventing the transcription of the cytokine genes 
(Shreiber & Crabtree, 1992).
The major drawback of these immunosuppressive modalities is that they 
are, to different extents, non-specific in their effects and result in significant side- 
effects related to their generalised immunosuppression. More specific types of
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immunosuppressive therapy have, therefore, been sought, in the hope that they 
will allow adequate suppression of the immune response without compromising 
the patients defences against opportunistic infections.
Anti-Thymocyte Globulin (ATG) and OKT3 are polyclonal and 
monoclonal antibodies, respectively, which are currently being used clinically to 
target those T cells which are thought to play the most important role in graft 
rejection.
A different approach to immunosuppression was explored in the 1970s 
after it was noticed that pre-operative blood transfusions seemed to have a 
beneficial, immunosuppressive effect in renal transplantation (Opelz, Sengar, 
Mickey et al, 1973). This led to a policy of routine pre-operative transfusions 
which, initially, improved overall graft survived rates. However, the beneficial 
effect of blood transfusion in graft survival has become marginal in recent years, 
due possibly to impovement in immunosuppressive therapy. Additionally, because 
blood transfusion may result in sensitization, with high levels of panel reactive 
antibodies in the serum of potential graft recipients who are then more likely to 
reject an allograft, this form of "immunosuppression" has been largely abandoned. 
However, there remains much experimental interest in the unexplained 
phenomenon of "tolerance" produced in some animal models of rejection by 
administration of a donor-specific blood transfusion a week prior to 
transplantation.
It remains the case, however, that the exact cellular and molecular 
mechanisms involved in the rejection of transplanted tissues are not fully 
understood, and without such knowledge it will be difficult to develop more 
precise methods of immunosuppression.
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Clinical observations of patient responses to grafts allowed a description 
of four different rejection tempos, each attributable to a different effector 
mechanism (Williams 1984):
a) Hyperacute rejection occurs within 24 hours of transplantation 
of a graft bearing major histocompatibility antigens (MHC Ag) to 
which the recipient has already been exposed and is an antibody 
mediated response.
b) Accelerated rejection occurs within five days of transplantation 
and may be either cell or antibody mediated.
c) Acute rejection occurs within the first three months after 
transplantation and is probably due to a combination of cell and 
antibody mediated response. It is the clinical equivalent of a first 
set response in the animal model.
d) Chronic rejection occurs any time after the first three months 
as the result of prolonged exposure to the MHC antigens of the 
graft.
It is not possible to study the cellular and molecular mechanisms of 
rejection in the clinical setting as, by necessity, all transplant patients are 
maintained on immunosuppressive drugs and their immune responses are, 
therefore, compromised. That knowledge which we already have of the rejection 
process is based for the most part, on work done with animal models, in which it 
is possible to examine unmodified rejection of tissue transplanted between 
different strains of the same species (allografts) or between different species 
(xenografts).
23
In addition, these models allow us to manipulate the immune response in 
an attempt to clarify the mechanisms involved.
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1:2 Initial Experimental Transplantation.
Current understanding of the immunological processes involved in the 
rejection of foreign tissue owes much to the pioneering work of the late Sir Peter 
Medawar. He had developed a keen interest in the treatment of severe bums, early 
in his career as a biologist and zoologist. This led him to spend a period of time 
working in the Bums Unit of Glasgow Royal Infirmary, collaborating with Mr. 
Tom Gibson, a local plastic surgeon.
At that time, it was know that treating severe bums by grafting skin from 
healthy donors would only work if the donor and the patient were identical twins. 
Grafts taken from unrelated donors were rapidly destroyed and would not "take".
Medawar and Gibson decided to treat a burns patient with skin taken from 
unaffected areas of the patients own body, and also with skin taken from her 
brother. In addition, she was given a further set of her brothers skin grafts, four 
days after the first.
It was noted that the first grafts from the brother were rapidly infiltrated 
with mononuclear cells and did not "take", while the second set of grafts were 
destroyed in an accelerated fashion, which has come to be known as "second set 
graft rejection". Medawar and Gibson suggested that this rejection was a specific 
response similar to that mounted by the body as a protection against infection. 
They observed that the rejection of the second set of grafts occurred in the 
absence of a cellular response and suggested that the "mechanism conforms to the 
general pattern of an antigen-antibody reaction" (Gibson & Medawar, 1943).
The patient and her brother were of the same blood group which led 
Medawar and Gibson to conclude that "blood compatibility is not sufficient, and 
is not known to be necessary, to ensure compatibility of the skin". It was apparent
25
that tissue incompatibility played an important role in determining the fate of a 
graft.
Back in England, Medawar continued his work in the field of 
transplantation with a series of experiments examining the rejection of skin grafts 
in rabbits (Medawar, 1944, 1945). This work demonstrated that the immune 
response to a graft was a systemic phenomenon; neither the site of origin, nor the 
site of transplantation of the graft had any influence on the rate of graft rejection. 
He also confirmed the results of his work on second set rejection with Gibson, and 
showed that this phenomenon was donor-specific, as it did not occur if the second 
graft was taken from a different donor from the first. Medawar went on to 
postulate the existence of tissue antigens which were capable of initiating a 
rejection response in rabbits, and suggested that graft survival time was dependent 
on the antigenic relationship between the donor and recipient.
This work laid the foundations of current transplantation immunology:
1) The graft rejection response is specific for the donor.
2) The response has memory and occurs in accelerated fashion 
when confronted with a second graft from the same donor (Second 
set rejection)
3) The first set response is primarily cell mediated.
Medawar was awarded the Nobel Prize for Medicine in 1960, in 
recognition of the importance of his early work in the field of transplantation.
Further fundamental contributions to the understanding of the processes 
involved in transplant rejection were to follow over the next twenty years.
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Gowans and his co-workers demonstrated a role for recirculating 
lymphocytes in mediating both antibody responses to antigens, and cell- 
mediated responses to skin allografts (Gowans, McGregor, Cowen et al, 
1962);
Snell proposed that the genetically determined histocompatibility antigens 
were responsible for the rejection of mismatched tissues (Snell, 1957);
The importance of thymically-processed T cells in a range of 
immunological responses was demonstrated by Miller (1962). These cells 
played a role in graft rejection, unlike the bursa-derived lymphocytes 
which had earlier been shown to be crucial in antibody responses, but not 
skin graft responses;
The clonal deletion theory of self tolerance was proposed and Billingham, 
Brent & Medawar (1956) who demonstrated the induction of neonatal 
tolerance.
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1:3 Major Histocompatibility Antigens
It is now fully accepted that the fate of tissue grafted from one individual 
to another, is dependent upon the antigens expressed on the cell surface, which are 
encoded by that area of the genome known as the Major Histocompatibility 
Complex (MHC), as put forward by Gorer et al in 1948 (Gorer, Lymans & Snell, 
1948). Incompatibility for MHC antigens between donor and recipient will lead to 
rapid rejection of transplanted tissue, whilst complete compatibility will afford a 
marked degree of protection to grafted tissue.
Although the MHC antigens are undoubtedly the most important 
determinants of graft survival or destruction, it is still possible for a graft to be 
rejected even when it is completely matched for MHC antigens. This results from 
incompatibilities of so-called minor histocompatibility antigens (mH) which are 
encoded outwith the MHC, but which have been shown to be capable of 
stimulating graft rejection in the presence of a full MHC match. This rejection is 
usually slower than that seen with an MHC mis-match but is no less destructive. 
The antigenic products of the mH loci are capable of activating either CTL or Tjj 
cells. The mH antigens that stimulate CTL have been shown to be peptides 
derived from intracellular proteins (Wallny & Rammensee, 1990; Griem, Wallny, 
Falk et al, 1991). In a recent review, Roopenian suggests that mH genes that 
encode products which stimulate Tjj cell reactivity will, typically, not in 
themselves constitute an effective transplantation barrier, possibly because the 
type or intensity of immunological activity induced is insufficient to lead to graft 
rejection even though the gene product is expressed by the allograft tissue. He 
argues that Tj^ cells and CTL commonly respond to antigens encoded by separate
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mH genes and that effective immunity requires both types of antigen (Roopenian, 
1992)
The first attempt to improve the results of transplantation by matching the 
donor and recipient tissues resulted in the identification of cell surface antigens on 
human leukocytes by Dausset in 1958 (Dausset, 1958). These Human Leukocyte 
Antigens (HLA) were first demonstrated on peripheral blood leukocytes and were 
found to be products of the MHC on chromosome six.
It was soon discovered that the antigens were not restricted to leukocytes, 
but were present on the surface on nearly all nucleated cells, and these are now 
known as class I MHC antigens.
Using serological techniques, clinical transplantation donors and recipients 
were matched for these antigens, with some improvement in results, but it was 
then found that cells which were apparently identical, as far as HLA was 
concerned, were capable of reacting with each other in mixed lymphocyte culture. 
This led to the discovery of a second group of surface antigens, also encoded by 
the MHC but with a much more restricted tissue distribution, which are now 
known as class II MHC antigens.
Our understanding of the roles played by these antigens in the rejection of 
transplanted tissue has been improved by the development and experimental use 
of inbred strains of laboratory animal, in particular the mouse and rat models. 
Much of the preliminary work was carried out using skin grafts in mice and, as the 
immunogenetics of the rat were unravelled, it became possible to perform 
vascularised organ grafts in the larger rodent. Further developments in 
microsurgical technique mean that it is now possible to perform whole organ 
vascular grafts between inbred strains of mouse (Corry, Winn & Russell, 1973).
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It should always be borne in mind, however, that although these animal 
models have many similarities with respect to the MHC, there are also important 
differences between species and indeed between strains of the same species, and 
care should be taken in interpreting the relevance of experimental data to the 
clinical transplantation setting.
1:3.1 The Major Histocompatibility Complex
The MHC genes which encode for the HLA system in man are found on 
chromosome six. The mouse MHC is on chromosome 17, while the location of the 
rat MHC encoding the RT1 is on chromosome 20.
1:3.2 The class I MHC region
In man, class I molecules are encoded by the HLA-A, HLA-B and HLA-C 
locus genes. In the mouse, class I molecules are encoded by the H-2D, H-2K and 
H-2L regions whereas , in the rat it is the RT1A region which encodes for those 
class I molecules of importance in transplantation. RT1C and RT1E antigens 
appear to play a lesser role in transplantation as it proved difficult to generate in 
vitro cytotoxic T lymphocyte responses against RT1C differences (Stock & 
Gunther, 1982).
1:3.3 The class II MHC region
Human class II molecules are encoded by the DR, DQ and DP regions of 
the HLA system. Mouse class II molecules are encoded by H-2I region genes, 
including IE which is analogous to human DR, and IA which is analogous to DQ.
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In addition, there is an IJ locus in the mouse which confers a suppressor function 
on T lymphocytes (Smith, Steinmetz & Hood, 1986)
The RT1B and RT1D regions encode for class II molecules in the rat, and 
are analogous to the IA and IE regions respectively (Blankenhorn, Cecka, 
Frelinger et al, 1980; Lobel & Cramer, 1981: Blankenhorn, Symington & Cramer,
1983).
1:3.4 The class III MHC region.
This region encodes for soluble proteins in all three species. These include 
complement components C2 and C4, and factor B, the serum-borne sex-linked 
protein in mice. Class III products play little part in initiating rejection of foreign 
tissue.
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1:4 Structure of MHC antigens
1:4.1 Class I antigens
The structure of class I antigens is similar in different species. They 
consist of two non-covalently linked glycoprotein chains with approximate 
molecular weights, in man, of 45 Kilodaltons (Kd) and 12 Kd.
The larger chain is a transmembrane protein with three extracellular 
domains, a l,a 2  and a3, each approximately 90 amino acids long and encoded on 
separate exons. Proximally a3 joins the transmembrane section which links with 
an hydrophilic intracellular region. Distally, a3 associates with the smaller light 
chain, |32-microglobulin ((32m). The a3 domain and (32m are relatively conserved 
and show amino-acid homology to immunoglobulin constant domains. The a l  
and a2 domains are polymorphic and show no significant sequence homology to 
immunoglobulin constant or variable domains. Bjorkman and co-workers studied 
the structure of crystals of purified HLA-A2 and found that the membrane- 
proximal a3 and (32m domains have tertiary structures resembling antibody 
domains, but are paired by a novel interaction not previously seen in 
immunoglobulin structures. The a l  and a2 domains are nearly identical to each 
other in structure, and are not similar to immunoglobulin variable or constant 
domains. The al and a2 domains form a platform composed of a single (3-pleated 
sheet topped by a-helices with a long groove between the helices (Figure 1.1). X- 
Ray crystallography reveals electron density, which is not a part of the HLA 
molecule, in the groove between the helices (Figure 1.2) and this was presumed to 
represent an unknown bound antigen (Bjorkman, Saper, Samraoui et al 1987).
It has now become accepted that this configuration of the MHC molecule 
is accurate and that the groove formed by the a l  and a2 domains is the site at
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Figure 1.1 The polypeptide structure of the HLA-A2 
class I molecule (Bjorkman et al, 1987)
* The three dimentional configuration of the 
extracellular region was established from the 
X-ray crystallographic structure of the HLA-A2 
molecule.
* The antigen binding groove was thought to be 
between the two a-helices of the a l  & a2  
domains.
Figure 1.2 The HLA-A2 molecule and antigen binding groove 
(Bjorkman et al, 1987).
* This Van der Waals surface representation of the top of the HLA-A2 
molecule shows:
a) The deep groove of the antigen binding site.
b) electron density in the groove (red), thought to represent antigen 
peptide.
which the MHC molecule binds either endogenous (self), or exogenous (foreign) 
peptides. The complex of MHC antigen and peptide can then be recognised by a T 
cell receptor, in conjunction with a CD8+ molecule.
1:4.2 Class II antigens
Class II antigens have a different, but in some respects similar, structure to 
class I antigens, in that they are composed of two polypeptide chains of 
approximately 33 and 28 Kd molecular weight.
Each chain has a short, hydrophilic, intracellular domain and a trans- 
membranous domain. In addition, each chain has two extracellular domains. 
Those domains next to the membrane are immunoglobulin-like with homology to 
class I a3 and p2m. The N-terminal end of the class II chains are presumed to 
contain the binding site for antigenic peptides and one of the domains has weak 
sequence homology to class I a l  and a2 (Bjorkman et al, 1987). It is thought that, 
as in the class I molecule, the membrane-distal domains form the site for peptide 
binding and recognition by T lymphocytes, in this case of the CD4+ phenotype. 
The alloantigenic specificity of the molecules is provided by the polymorphic 
nature of the membrane-distal domains.
1:5 Tissue distribution of MHC antigens
Class I antigens are expressed by nearly all nucleated cells, and in 
particular on interstitial dendritic cells and vascular endothelium, whereas Class II 
antigens have a much more restricted tissue distribution. They were originally 
thought to be restricted to B lymphocytes, macrophages, monocytes and dendritic 
cells.
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It is now apparent, however, that the expression of both class I and class II 
antigens is not an all-or-none phenomenon, and either, or both, can be up- 
regulated (or down-regulated) under certain conditions. Lampert, Suitters & 
Chisolm (1981) demonstrated, in rats, the expression of class II antigen on 
epidermal cells, which do not normally express class II, during a graft-versus-host 
reaction, and this finding was confirmed by Mason et al (1981). Subsequent 
reports have shown the induction of class II expression on mouse and rat 
endothelial cells and keratinocytes in skin grafts undergoing rejection (de Waal, 
Bogman, Maass et al, 1983: Dallman & Mason, 1983). Induction of class I and 
class II antigens has also been described in vascularised heart and renal grafts in 
the rat model (Milton & Fabre, 1985; Milton, Spencer & Fabre 1986a). They 
demonstrated the specific induction of MHC antigens on donor tissue , and were 
able to show highly positive induction of class I and class II antigens on donor 
myocardial cells, which normally express very little class I, and no class II, 
antigen. In addition, they showed high levels of class II induction in both cardiac 
and renal vascular endothelium and it is well recognised that the endothelium of a 
vascularised graft is the initial interface between the recipient's immune response 
and the foreign tissue (Adams et al, 1989; Bishop et al, 1989).
The rejection of other whole organ grafts such as liver and pancreas is also 
associated with up-regulation of MHC products. In the rat, rejection of the 
pancreas is associated with induction of class II antigens on acinar cells, 
pancreatic duct epithelium and vascular endothelium, while the islets of 
Langerhans remain class II negative (Steiniger, Klempnauer & Wonigeit, 1985). 
Both human and rat liver allografts are rejected in unmodified hosts, with 
induction of class II MHC antigens on bile duct epithelial cells, whilst hepatocytes 
remain class II negative (Takacs, Szende, Rot et al, 1985).
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1:6 The role of MHC antigens in transplantation
The MHC and its* antigenic products are the most important factor in 
determining whether grafted, foreign tissue is accepted by the recipient or is 
recognised as foreign and rejected by way of the immune response.
The biological function of both class I and class II MHC antigens is to 
present processed antigenic peptide fragments, of either endogenous "self' or 
exogenous "foreign" origin, to T lymphocytes, which recognise and respond to the 
complex of MHC molecule and presented peptide. In this process, cytotoxic T 
lymphocytes (CTL) of the CD8+ phenotype recognise only class I MHC 
molecules, while T helper (Tjj) lymphocytes of the CD4+ phenotype interact only 
with class II molecules (Bach, & Sondel, 1976; Miller, Vadas, Whitelaw et al, 
1976).
T cells also have the capacity to recognise and react to allogeneic MHC 
molecules on transplanted tissue and this results in a strong, and specific, immune 
response, leading to the destruction of the foreign tissue. Alloantigen will 
typically stimulate a response in approximately 10% of peripheral T cells as 
compared to less than 1% which are stimulated by exposure to nominal antigens. 
Complete MHC incompatibility leads to rapid graft rejection but it has also been 
demonstrated, using inbred animal strains, that isolated MHC disparities of either 
class I or class II can result in the rejection of the grafted tissue, albeit usually at a 
slower tempo than full MHC incompatible tissue (Katz, Liebert, Gill et al, 1983; 
Burdick & Clow, 1986).
Although the MHC antigens are of crucial importance in the initiation of 
the rejection process in transplantation, it is still possible for grafted tissue to be 
rejected in the presence of an identical MHC match, such as that between identical
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twins (as discussed earlier). This rejection is as a result of incompatibilities of the 
minor histocompatibility (mH) antigens, which are encoded outwith the MHC.
An example of such a mH antigen is Epa-1 which is expressed only on 
epidermal cells of mice, rats and man (Steinmuller & Tyler, 1983). 
Incompatibility of this antigen leads to skin graft rejection and the generation of 
Epa-specific cytotoxic T lymphocytes. There are many other mH antigens whose 
ability to stimulate an immune response may be of clinical importance.
1:7 The role of cytokines in regulation of MHC expression
The alteration of cellular expression of MHC antigens is brought about, in 
transplanted tissue, by soluble mediators (cytokines) released by leukocytes 
infiltrating the graft. Foremost among these mediators is gamma-interferon (IFN- 
y) which is produced by activated T lymphocytes and has been shown to induce 
the expression of both class I and class II antigens in vitro and in vivo. In addition, 
both alpha and beta interferon, which are produced by a wide variety of cells, are 
capable of inducing class I antigens in vitro (Fellous, Nir, Wallach et al, 1982; 
Wong, Clark-Lewis, Harris et al, 1984; Basham, Smith, Larnier et al, 1984; 
Halloran, Madrenas, 1990).
It is likely that the induction of class II antigens, or the up-regulation of 
their expression as a result of the influence of cytokine mediators, will facilitate 
the interaction of MHC molecules with CD4+ T lymphocytes and thereby 
augment the production of an effective immune response against the foreign 
tissue.
This concept is strengthened by the fact that preventing the up-regulation 
of MHC antigens by, for example, Cyclosporin A (CyA) was associated with the 
acceptance of an allograft which would have been rejected by an unmodified
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recipient (Milton, Spencer & Fabre, 1986b). Groenewegan and co-workers also 
demonstrated that class II expression was lost from kidney endothelial cells of 
dogs in which lymphokine production was inhibited by treatment with CyA 
(Groenewegan, Buurman & van der Linden, 1985). Steroids are also capable of 
preventing the induction of class II antigens by IFN-y, as demonstrated by 
Leszczynski et al in 1986. They found that a single dose of IFN-y markedly 
increased class II expression on rat renal endothelial cells, and that this effect was 
completely abolished by three daily doses of methylprednisolone (Leszczynski, 
Ferry Schellekens et al, 1986). It has also been shown that the induction of MHC 
antigens in rat renal allografts can be prevented by continuous local infusion of 
steroids (Ruers, Buurman, van Boxtel et al, 1987).
1:8 CD4 and CD8 cell surface molecules.
The expression of the CD4 or CD8 molecules on the surface of peripheral 
T cells is mutually exclusive. The presence of CD4 or CD8 molecules restrict the 
cells to recognition of antigens presented in the context of MHC class II and class
I respectively. What is not fully understood is the exact role of these molecules in 
the recognition process and in the subsequent activation of the T cells. Biddison 
and co-workers first suggested that the CD4 molecule was separate from the TCR 
and had a binding site for a non-polymorphic epitope on class II MHC molecules 
(Biddison, Rao, Talle et al, 1982), and this was borne out by the finding that cells 
infected with a high expression SV40 vector containing a CD4 cDNA acquire the 
ability to specifically bind to cells that express various allelic forms of HLA class
II molecules, and that this binding could be inhibited by anti-CD4 monoclonal 
antibodies (Doyle & Strominger, 1987). In this in vitro work, however, the CD4 
expression was far in excess of physiological levels and while it demonstrates the
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ability of CD4 to bind with class II MHC, it does not address the question of 
whether CD4 plays any further role in T cell activation. Subsequent work by 
Biddison and Shaw, looking at CD4+ CTLs which were specific for class II MHC, 
showed that anti-CD4 mAh blocking could abrogate the action of these CTLs, 
further suggesting a role for CD4 in MHC recognition. In addition it was found 
that CD4 was of greater relative importance in facilitating interactions between 
TCR and MHC which were of "low-affinity". They concluded from this work, 
using human CTL clones, that the CD4 molecule had only a minor role in 
adhesion, per se, and that, as not all adhesions led to cell lysis, some further 
mechanism must be at play in the post-adhesional phase of cytotoxic T-cell 
recognition (Biddison & Shaw, 1989).
It is now apparent that the cytoplasmic domains of CD4 and CD8 have a 
physical association with a protein tyrosine kinase activity, known as p561ck, and 
as tyrosine phosphorylation is a major signal transduction system involved in the 
regulation of cell growth, it seems probable that it is acting as a signal for cell 
activation as a result of stimulation by CD4 or CD8 (Ruud, Trevillyan, Dasgupta 
et al, 1988; Veillette, Bookman, Horak et al, 1988). Other workers have 
demonstrated both stimulatory and inhibitory signals to T cells, mediated by the 
CD4 molecule, and independent of MHC recognition (Rosoff, Burakoff & 
Greenstein, 1987; Bank & Chess, 1985). These findings have led to the suggestion 
of the CD4 molecule being an integral part of the TCR ( a co-receptor) for class II 
MHC, and not simply an accessory molecule which augments the interaction 
between the TCR and the MHC molecule (Janeway, Rojo, Saizawa et al, 1989).
The CD8 molecule acts in the similar fashion to CD4, but in association 
with its TCR it binds to a non-polymorphic region on class I MHC molecules.
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1:9 Mechanisms of allograft rejection
The great increase in the number of clinical transplants, of various organs, 
now being performed world-wide is mirrored by the level of research into the 
exact mechanism, or mechanisms, by which the transplanted organs are being 
rejected by their recipients. It is recognised that the rejection process is extremely 
complex and multifactorial. In order to try to simplify matters it is convenient to 
consider the rejection of an allograft as consisting of three phases. These are:
1. The afferent phase
2. The central phase
3. The efferent, or effector, phase
1:9.1 The afferent phase of graft rejection
The afferent phase of allograft rejection refers to the process whereby the 
immune system of the recipient recognises the graft antigens as foreign, i.e. non­
self, and becomes primed to initiate rejection. For this to occur, the alloantigens of 
the graft must be presented to the host lymphocytes. In the context of the normal 
physiology of the immune system, the T cell receptor recognises foreign antigens 
as peptide fragments in association with self MHC class I or II molecules. In 
allograft recognition, however, the recipient T cells recognise the whole foreign 
MHC molecule as being non-self, on the surface of allogeneic cells. In addition, it 
is now thought that these alloantigens can be processed by antigen presenting cells 
(APC), of donor or host origin, and presented by the APC to recipient sensitized T 
cells in a complex of MHC molecule and bound peptide. This complex is 
recognised by the T cell receptor (Shimonkevitz, Kappler, Marrack et al, 1983).
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The most efficient APC belong to a group of bone-marrow derived, 
interstitial cells with a distinctive spicular morphology, known as dendritic cells. 
These cells are typically isolated from lymphoid tissues such as the spleen, are 
non-phagocytic and express the leukocyte common antigen (CD45). The 
lymphoid dendritic cells belong to a widely distributed and diverse lineage of 
dendritic leukocytes but the lymphoid subgroup appears to be a specialised 
immunostimulatory cell which, in addition to antigen presentation to sensitised T 
cells, has the ability to deliver an activation signal to resting T cells. The nature of 
this signal remains obscure.
Because of the immunostimulatory nature of the lymphoid dendritic cell 
and the fact that dendritic leukocytes are found in the parenchyme of all 
commonly transplanted tissues, and, indeed, are found in all tissues with the 
exception of the nervous system (Hart & Fabre, 1981; Daar, Fuggle, Fabre et al,
1984), it is now accepted that the non-lymphoid dendritic leukocytes may be 
important passenger leukocytes in transplantation. They express high levels of 
MHC class I and class II antigens on their surface and are potent stimulators of the 
in vitro mixed lymphocyte reaction (Steinman & Witmer, 1978; Mason, Pugh & 
Webb, 1981). They may present antigen to host circulating lymphocytes within 
the graft itself or following migration to the draining lymph nodes. It is also 
possible that the antigens, on donor APC, may be shed from the graft and interact 
with recipient APC and T cells within the draining lymph nodes. In a recent 
review of the migration patterns of dendritic leukocytes Austyn & Larsen point 
out that dendritic leukocytes can capture antigen in the periphery and transport it 
to draining lymph nodes, where they induce immune responses, in addition 
Austyn has shown, using double-labeling techniques with fluorochromes that, 
following intravenous administration, labelled dendritic cells migrate to the T
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areas of the spleen but he was not able to find any migration of host dendritic cells 
into a vascularised allograft. This group has subsequently found that following a 
cardiac allograft donor-type dendritic cells were found in the recipient spleen, 
concomitant with a reduction in the number of dendritic leukocytes in the donor 
heart. Austyn is, therefore, of the opinion that sensitization to an allograft occurs 
centrally either via the lymphatics draining the graft or via the blood (Austyn & 
Larsen, 1990). Other cell types, such as endothelial cells, also have the capacity to 
act as antigen presenting cells, but this is usually less efficient than the 
"professional" APCs (Hirschberg et al, 1981).
Interestingly, it has been shown that, in the case of skin grafts, prolonged 
survival of an allograft can be achieved experimentally by preventing the 
restoration of lymphatic drainage (Barker & Billingham, 1968), whilst in 
primarily vascularised organ grafts lymphatic diversion had no effect on graft 
survival (Pederson & Morris, 1970). These results suggest that the lymphatic route 
is central in the sensitization against a skin graft, in which the vascular supply 
takes some time to mature, whereas it is of less importance in the rejection of a 
primarily vascularised organ graft.
The importance of the interstitial dendritic cell in the initiation of the 
rejection of an allograft was demonstrated by Lechler and Batchelor (1982). They 
transplanted a rat kidney into an intermediate host which was syngeneic with the 
eventual recipient, but which had been pre-treated with donor alloantibody to 
prevent rejection of the kidney (passive enhancement). The kidney was left in the 
intermediate host for several weeks to allow its bone-marrow derived dendritic 
cells to be replaced by those of recipient origin.
The kidney was then re-transplanted into the final host, which was 
syngeneic with the intermediate host, and it was found that the graft was not
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rejected. Simultaneous injection of 10^ donor strain dendritic cells was, however, 
sufficient to fully restore graft rejection. Although most of the re-transplanted 
hearts were rejected prior to reconstitution with donor-strain dendritic cells, some 
were not. The authors argued that this finding could be explained by the indirect 
pathway of antigen presentation, with the donor MHC being processed by the 
recipient strain dendritic cells in the intermediate host and presented by these 
recipient APCs to recipient T cells in the final graft recipient. A more detailed 
examination of the concept of indirect antigen recognition will be undertaken later 
in this thesis.
Prior to this work, blood-borne leukocytes of donor origin which had been 
trapped in the graft (passenger leukocytes) were suspected of being important in 
alloantigen presentation and sensitization against the graft, but it could not be 
demonstrated that elimination of these cells, or the use of radiation bone-marrow 
chimeric rat donors in which the passenger leukocytes were syngeneic with the 
recipients, could produce long-term graft survival, although some prolongation of 
survival was seen (Guttman, Lindquist & Ockner, 1969; Stuart, Bastein, Holter et 
al, 1971). More recently the possibility of targeting these passenger leukocytes 
with monoclonal antibodies prior to insertion of a vascularised graft, in an attempt 
to decrease the antigenicity of the graft, has become a reality, and is now 
undergoing assessment in clinical trials.
As the presentation of alloantigen is crucial in the development of the 
immune response to a graft, other cell lines have been examined to assess their 
ability to express class II MHC antigens. Pober et al showed in 1983, that human 
umbilical vein endothelial cells which had been cultured with IFN-y developed an 
increased expression of Class II antigens which were able to interact with 
allospecific CTL (Pober, Collins, Gimbrone et al, 1983). It has also been
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demonstrated that rat heart endothelial cells cultured in vitro with IFN-y are 
induced to express increased class II, and these cells could sensitize an allogeneic 
host to rapidly reject an allograft (Ferry, Halttunen, Leszczynski et al, 1987).
Although it has become accepted that the vascular endothelium of an 
organ graft is the primary target for the effector arm of the rejection response, its 
role in the presentation of alloantigen, and thereby the initiation of the immune 
response, is much less clear and remains controversial. However, it is known that 
human umbilical vein endothelial cells can stimulate allogeneic lymphocytes in 
mixed cultures (Hirschberg et al, 1975), and can also present soluble protein 
antigens to stimulate purified T cells, in association with class II MHC antigen 
products on the endothelial membrane (Hirschberg, Scott, Thorsby, 1981). 
Hirschberg argues that antigen presentation may be the physiological role of MHC 
antigen on endothelial cells, and that allograft rejection by the destruction of a 
grafted organ's vasculature may be a by-product of it's role in antigen 
presentation. The potential role of vascular endothelium in antigen presentation 
remains the focus of much current research.
1:9.2 The central phase of graft rejection
The central phase of graft rejection is concerned with the initiation of 
effector mechanisms of rejection, as a result of interactions between APC and 
lymphocytes, and between lymphocyte subsets. This process takes place, in the 
main, in the draining lymph nodes and the recipient spleen. It has been shown that 
recirculating T lymphocytes play the central role in recognising antigen and 
stimulating the proliferation of B lymphocytes in lymph nodes and the production 
of allospecific lymphocytes, which then invade the grafted tissue (Gowans, 
McGregor, Cowen et al, 1962).
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Bone-marrow derived cells with dendritic morphology and a high level of 
Class II MHC antigen expression have been demonstrated in the thymus 
dependent region of lymph nodes (Barclay, 1981). Recognition of the class II 
molecule by CD4+ T lymphocytes results in the activation of these Tj_j cells, 
which play a central role in this phase of the rejection response (Mason & Morris, 
1986). The exact mechanism of T cell activation is not yet fully understood, but 
will be discussed later in this thesis. Once activated, the Tjj cell produces 
lymphokines, of which the best known and most studied is interleukin-2 (IL-2), 
which result in the proliferation and differentiation of various effector 
mechanisms involved in the immune response, such as the differentiation of 
cytotoxic T cells, the activation of macrophages and natural killer (NK) cells, and 
the clonal proliferation of allospecific B cells producing alloantibody which may 
lead to an antibody dependent cellular cytotoxicity reaction or complement 
mediated damage to the graft. In addition, as has been mentioned earlier, 
lymphokine production by Tjj cells results in induction of Class I and class II 
MHC antigen expression on grafted tissue and increases their susceptibility to 
attack by effector limbs of the rejection process.
The nature, and relative importance, of the various effector mechanisms of 
transplant rejection will be discussed in detail in the remainder of this thesis.
1:9.3 The effector phase of graft rejection.
The rejection of an allograft by an unmodified recipient is a predictable 
and rapidly, destructive phenomenon. It does not occur, however, as the result of 
any one effector mechanism, but rather as a multifactorial, complex group of 
reactions, which can only be separated and studied in the experimental animal. In 
particular, the development of inbred animals has allowed us to greatly increase
44
our understanding of the individual effector limbs which make up the immune 
response to organ grafts.
There has been, and continues to be, much debate over the relative 
contributions of a delayed-type hypersensitivity reaction (DTH); specific 
cytotoxic T cells (CTL); helper T cells (Tjj); antibody-dependent cellular 
cytotoxicity (ADCC), and complement-dependent, alloantibody mediated, cell 
killing. Each of these will be considered in the following section.
1:9.3.1 Delayed type hypersensitivity (DTH).
When Brent, Brown and Medawar looked at the morphology of the 
cellular infiltrate in rejecting skin grafts in 1958, they observed that it was similar 
to the infiltrate seen in a classical delayed-type hypersensitivity reaction and they 
postulated that this was the likely mechanism involved in allograft rejection 
(Brent, Brown, Medawar, 1958).
In a DTH response, Tj_j cells which have been activated by recognition of 
donor class II MHC molecules, produce a number of lymphokines, notably IL-2, 
which have the effect of activating non-specific effector cells such as 
macrophages and NK cells. These cells will destroy foreign tissue but, in keeping 
with their lack of specificity, they will also cause some damage to surrounding 
"self" tissue.
It has been reported that both of these non-specific cells (macrophages and 
NK cells) are present in large numbers in rejecting grafts but, owing to technical 
difficulties in isolating them, it has proved difficult to closely examine their role 
in rejection, to the degree that has been possible with T cells. One striking piece 
of evidence which suggests that any role they play is entirely secondary, and 
dependent on the presence of T cell help, is the fact that congenitally athymic
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animals, and ATXBM animals, are both unable to reject any kind of allograft, 
despite the presence of both NK cells and macrophages within the graft. These 
cells may play a role in rejection in conjunction with Th cells, or indeed antibody, 
as they both possess an Fc receptor and could be involved in ADCC, but they 
cannot reject an allograft on their own.
1:9.3.2 Cytotoxic T lymphocytes (CTL) and helper T lymphocytes (Tjj).
There is now no doubting the central importance of the T cell in the 
regulation of rejection of an allograft. As has been mentioned previously, 
congenitally athymic rodents and ATXBM animals, which are devoid of T cells, 
are unable to reject an allograft although the grafts contain a heavy infiltrate of 
non-specific effector cells. Reconstitution of such animals with T cells restores 
their ability to reject the allograft. The difficulty arises in determining which type 
of T cell is more important and how do they interact with other cell lines to 
produce rejection of the graft. A great deal of time and effort has been put in to try 
to solve these problems in recent times, which have gradually increased our 
knowledge of the extreme complexity and adaptability of the immune system. The 
fact that much of this work has, by necessity, been carried out in laboratory 
animals must be borne in mind, as many of the results are species or strain- 
specific, and can be completely reversed by performing the same experiment in a 
different strain combination. In spite of these limitations, the rodent models have 
been invaluable as a tool to assist in the unravelling of the very complex cellular 
interactions which are taking place.
The main subdivision of T cells is into those cells which are able to 
directly lyse target cells, the CD8+ CTL, and those which, by release of 
lymphokines, provide help for a variety of other cell types to differentiate and
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become activated, the CD4+ Tpj cell. Both of these subsets express the T cell 
receptor (TCR) on their surface and through this they recognise MHC antigen 
presented to them on the surface of APC. It is known that the CD4+ Th is 
restricted to class II MHC while CD8+ CTL recognise only class I MHC. In the 
light of the knowledge that foreign MHC antigens present on an allograft can be 
processed by host APC and presented to the T cell as peptide in the groove of 
class II MHC, it seems possible that the CD4+ T cell may be of greater 
importance in regulating the rejection of the antigen source.
In 1960, Govaerts demonstrated that thoracic duct lymphocytes taken from 
dogs which had rejected an allograft, had the ability to specifically lyse donor- 
type kidney epithelial cells in vitro (Govaerts, 1960). This was the first evidence 
that a CTL may be an effective mediator of graft rejection. It has subsequently 
been shown that such CTL cause cell killing by direct action, involving cell-to- 
cell contact, but without the involvement of lymphokines or of non-specific cells 
such as macrophages or NK cells. CTLs are of the CD8+ phenotype and express 
the CD8 molecule on their cell membrane in close association with the T cell 
receptor (TCR). This complex of TCR and CD8 is restricted to recognition of 
class I MHC molecules. In the presence of a full MHC disparity, however, 
differentiation of CTL precursors is greatly enhanced by the action of CD4+ Th 
cells which respond to the class II MHC molecules (Bach, Bach, Sondel, 1976).
Important demonstrations of the specificity of the graft rejection response 
came with the work of Mintz and Silvers (1970) and Rosenberg & Singer (1988). 
They developed allophenic mice by fusing blastomeres of two different H-2 
strains and then grafted skin from an allophenic donor onto one of the parental 
strains. One of the parental strains used was white, while the other was black. 
They found that the hair follicles of the foreign parental strain were destroyed,
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while those follicles that were syngeneic to the host, were undamaged, thus 
providing convincing evidence for a highly specific immune response which was 
assumed to be mediated by CTLs.
Following the work of Mintz and Silver, the concept of CTL rejection was 
a popular one. By examining the phenotype and functional capabilities of day 5 
infiltrating cells from rat renal allografts, Bradley and co-workers demonstrated 
that in grafts undergoing unmodified rejection there was a high level of specific 
cytotoxic T cell activity, but this was lost in cyclosporin treated, and passively 
enhanced animals which did not reject their grafts (Bradley, Mason, Morris,
1985). In addition they found that the number of non-specific, cytotoxic cells was 
similar in rejecting and non-rejecting grafts. From this work they concluded that 
the effector mechanism in their model was the CTL, although it was pointed out 
that no other effector mechanisms had been evaluated.
Interestingly, Loveland & McKenzie (1981 & 1982) and Dallman, Mason 
& Webb (1982), found, in mice and rats respectively, that adoptive transfer of 
CD4+, and not CD8+, cells restored skin graft rejection in ATXBM animals. 
Dallman noted, however, the presence in the rejected graft of large numbers of 
CD8+ cells and macrophages of host origin which gave rise to the theory that, in 
such animal models, the transfer of CD4+ T cells may result in the maturation and 
activation of CD8+ precursors of host origin, which may become the effector 
cells, acting as CTL. There is, however, increasing evidence that, although CD8+ 
CTL may play a role as an effector cell, it is the CD4+ Th cell which is central in 
regulating graft rejection. Adoptive transfer of CD4+ T cells can restore the 
rejection of vascularised heart and kidney grafts in acutely irradiated rats across a 
full MHC disparity (Hall, de Saxe & Dorsch, 1983: Gurley, Lowry & Clarke 
Forbes, 1983) although, here again, there are CD8+ cells of host origin found in
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the rejecting graft which could be acting as effector cells, and the exact 
mechanism of Th effects remained unclear.
In keeping with accepted MHC restrictions, Lowry, Clarke Forbes, 
Blackburn et al (1985) showed, that the adoptive transfer of CD8+ cells was 
required for the rejection of a class I disparate cardiac allograft. This evidence for 
a direct role for CD8+ CTL was strengthened by the finding that the rate of 
rejection of an isolated class I disparate skin graft between Kbm and B6 mice, was 
dependent upon the number of Kbm-reactive, Lyt 2+ (CD8) IL-2 secreting T cell 
precursors which could be generated in mixed Kbm x B6 lymphocyte cultures, 
and that the restoration of rejection of bml skin by a B6 nude mouse was 
dependent on the presence of Lyt 2+ (CD8) cells alone (Rosenberg, Mizuochi & 
Singer, 1986). In contrast, however, using the congenitally athymic PVG nude rat, 
it has been shown that rejection can be restored rapidly by adoptive transfer of 
isolated CD4+ T cells whereas it is significantly delayed by transfer of CD8+ 
cells alone (Mason & Simmonds, 1988). Using a different model, namely an 
acutely irradiated DA rat recipient, Hall et al found that while rejection could be 
restored by CD4+ cells alone, the effect of transfer of combined CD4+ and CD8+ 
T cells was an even more rapid rejection response (Hall, Gurley, Dorsch, 1985).
This finding adds weight to the argument of a central role for the CD4+ T 
cell, with one of it's effects being activation of CD8+ cells. Interestingly, in 
subsequent experiments, Hall and co-workers found that CD4+ cells restored graft 
rejection in acutely irradiated rats which had additionally been treated with anti- 
CD8 monoclonal antibody (mAb) MRC 0x8 to deplete any residual CD8+ cells, 
and they found that rejected grafts were completely free of CD8+ cells but were 
infiltrated by CD4+ cells and host macrophages. They also noted that the hosts did 
not produce alloantibody against the grafts (Hall, Pearce, Gurley et al, 1990). In
49
addition, they found that the acutely irradiated rats that were treated with MRC 
0x8 but were not given any cells, were also able to reject their grafts and they 
argued that CD4+ cells which remained following irradiation, or had regenerated, 
were alone sufficient to cause rejection, and that the CD8+ cells, in this model, 
were acting as suppressor cells. An alternative explanation for this rejection has 
recently been put forward by Rosenberg et al (1991). They describe the possible 
existence of a tiny population of CD8+ T cells which, instead of being depleted by 
anti-CD8 mAb therapy, are in fact activated by it and are, alone, capable of 
causing graft rejection even in the presence of massive, but they argue not 
complete, CD8+ T cell depletion. The evidence for this is not convincing, as yet. 
It has also been demonstrated, in the rodent model, that CD8+ cells can be 
activated independently of CD4+ cells, and result in the rejection of a class I 
disparate graft (Rosenberg, Mizuochi, Sharrow et al, 1987). In direct contrast, 
however, Gracie et al found that kidney grafts bearing an isolated class I disparity, 
in a rat model, were rejected in the absence of CD8+ cells or of specific CTLs. In 
addition, it was shown that these rats produced specific alloantibody against their 
graft, and transfer of rejecting serum could restore rejection to cyclosporin treated 
animals (Gracie, Bolton, Porteous et al, 1990). This result raises the possibility of 
an important role for alloantibody in the mediation of acute allograft rejection. 
This question will be discussed in greater detail later in this thesis.
In a recent review of the experimental evidence relating to allograft 
rejection, Hall concludes that the data from mAb depletion experiments suggest 
that CD4+ cells mediate class II MHC-incompatible graft rejection, and CD8+ 
cells mediate class I MHC-incompatible graft rejection, with CD8+ cell activation 
being dependent upon CD4+ cells to varying degrees (Hall, 1991).
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1:9.3.3 The role of alloantibody in acute rejection.
It is widely accepted that the uncommon clinical phenomenon of 
hyperacute rejection (i.e. within 24 hours of transplantation) of an allograft is 
mediated by pre-formed, circulating host antibody against the grafted tissue MHC 
antigens (Kissmeyer-Nielsen, Olsen, Petersen et al, 1961; Patel & Terasaki, 1969; 
Williams, Hume, Hudson et al, 1968). The antibody binds to the vascular 
endothelium of the graft and sets off a sequence of events including complement 
fixation, platelet aggregation, fibrin deposition and, ultimately, destruction of the 
microvasculature and the graft itself (Busch, Reynolds, Galvanek et al, 1971). In a 
recent review of the place of alloantibodies in transplant rejection Baldwin argues 
that irreversible antibody-mediated rejection of a large multicellular organ is not 
due to the immune lysis of individual cells, but is as a result of the damaging 
effect of multiple potent inflammatory cells and factors that antibody and certain 
complement fragments are capable of attracting and activating to cause tissue 
damage (Baldwin, Pruitt, Sanfilippo, 1991). In the clinical setting it is pre-formed 
antibodies to class I MHC and to ABO blood group antigens which are 
particularly implicated in hyperacute rejection (Baldwin et al, 1991), but the 
clinical incidence of this problem has been greatly reduced by pre-operative 
testing of the recipients serum for the presence of alloantibodies against a panel of 
standardised antigens (Patel & Terasaki, 1969). Although IgM is the most 
efficient class of antibody at activating complement in vitro, it is IgG which is 
more harmful to the transplanted organ (Baldwin et al, 1991). This incongruous 
finding may be due to the fact that many of the positive crossmatches to IgM are 
the result of autoantibodies (Barger et al, 1989; Lobo, 1981), or immune 
complexes (Baldwin et al, 1986; Wang, Terashita, Terasaki, 1989), neither of 
which cause any harm to allografts, and an artificial impression is given as to the
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importance of IgM as a result of the in vitro assays. It remains an undeniable fact, 
however, that alloantibody can, and does, cause hyperacute graft rejection.
A second potential mechanism by which alloantibody could mediate a 
rejection response is by "antibody dependent cellular cytotoxicity", or ADCC. 
This involves adherence of specific alloantibody to the MHC antigens of foreign 
cells, and the Fc portion of the antibody is then recognised by host macrophages 
and NK cells, both of which have Fc receptors. These effector cells then bring 
about the specific destruction of the allograft. It has been shown that, in the rat, 
IgG can both activate complement and mediate target cell cytotoxicity through 
activation of killer cells by the Fc receptors (Baldwin, Rhoton, Sanfilippo, 1991; 
Chassoux et al, 1988). As Fc receptors, of one or more types, are present on the 
surface of platelets, neutrophils, eosinophils, macrophages, NK cells and B 
lymphocytes, it can be easily understood that many acute and chronic 
inflammatory events may be mediated by the interaction of antibody with the 
broad array of Fc receptor-bearing cells (Petty, Francis, Anderson, 1989). It 
remains controversial, however, whether alloantibody plays a significant role in 
the acute rejection of an allograft (which is a far commoner clinical problem than 
hyperacute rejection), and this question must be addressed prior to any 
consideration of the mechanisms by which alloantibody might be effective.
As the concept of a cellular basis of acute rejection has been popular, so 
the experimental investigation of the role of alloantibody in this type of rejection 
response has been rather neglected. It has been known for some time that the 
adoptive transfer of immune serum can result in enhancement of renal allografts 
(French & Batchelor, 1969), and that this was easier to obtain in an FI graft than a 
homozygous graft, in which the amount of antibody required to produce an effect 
was likely to tip the balance in favour of hyperacute rejection (McDowall,
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Batchelor, French, 1973; Fabre & Morris, 1974). Fabre and Morris also found 
that, in certain strain combinations, passive transfer of alloantibody only resulted 
in hyperacute rejection and, consequently, they advised caution in the 
interpretation of previous experimental findings relating to alloantibody-mediated 
enhancement, and any potential clinical application of such findings.
In 1984, Lowry & Clarke Forbes reported that humoral antibody was not 
required for the acute rejection of a cardiac allograft in the rat (Lowry, Clarke 
Forbes, 1984). This statement was based on ultrastructural observations of 
rejecting, irradiated hearts in irradiated recipients, which had been reconstituted 
with unfractionated spleen cells syngeneic with the recipient, or with spleen cells 
which had been depleted of B cells. They found that rejection of the graft took 
place, in a similar ultrastructural fashion to unmodified controls, in those animals 
given B cell-depleted splenocytes, and in which there was no demonstrable 
alloantibody response. Earlier, it had been found, in a sheep model of renal 
allograft rejection, that graft rejection was associated with high levels of specific 
alloantibody production, and that the passive transfer of rejecting serum, given at 
the time of transplantation, resulted in a more rapid rejection response (Pedersen 
& Morris, 1974). Further evidence for a role in acute allograft rejection for 
alloantibody was presented by Gracie and co-workers (Gracie et al, 1990), who 
showed that immune serum from RTlu rats rejecting a class I disparate kidney 
(R8), was able to restore specific rejection of a class I disparate graft to an RTlu 
recipient which had been treated with cyclosporin to prevent rejection. They also 
demonstrated that the cyclosporin treatment had abrogated the recipients own 
alloantibody response to the renal allograft. These interesting results suggest that, 
in this model at least, alloantibody is capable of effecting acute allograft rejection.
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1:9.3.4 Summary of effector mechanisms
Whilst it is true to say that our knowledge of cellular and humoral 
interactions in the process of allograft rejection has greatly increased, it is also the 
case that the complexity and variability of these events is becoming ever more 
apparent.
There is general agreement on the crucial, and central, role of the CD4+ T 
cell in the regulation of rejection events by providing T cell help, in the form of 
cytokines, for the differentiation and activation of both CD8+ cells and of 
antibody-producing B cells.
Experimental evidence has confirmed that both CD4+ class II-restricted, 
and CD8+ class I-restricted T cells are capable of mediating rejection in strictly 
controlled laboratory conditions. Equally, there is increasing interest in the 
possibility that alloantibody may be a more important effector arm than has been 
thought up until now.
These experimental advances in examining the individual components of 
the rejection response mounted against an allograft have already led to the 
introduction of more specific forms of immunosuppression into clinical 
transplantation practice. The prevention of rejection still remains the greatest 
challenge in the field of organ transplantation, however, and we are still a long 
way from fully understanding the factors which influence, and control, the 
interactions between the various arms of the effector phase of the rejection 
process.
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1:10 Aims of this thesis
The primary aim of this thesis is to address the mechanism of rejection of 
an isolated, class I disparate, cardiac allograft in a rat model, with particular 
emphasis on the role of specific alloantibody produced against the graft by the 
recipient animal.
To study cellular events involved in the rejection of such a graft, T cell 
subsets were depleted, in vivo, using monoclonal antibodies, against CD4+ and 
CD8+ T cells, injected intraperitoneally at, and following, the time of 
transplantation.
Finally, this thesis considers the mechanisms by which alloantibody might 
effect tissue damage in this model of cardiac allograft rejection.
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CHAPTER TWO 
MATERIALS AND METHODS
56
2:1 Animals
Inbred male rats were used throughout this work. These were obtained 
from Harlan Olac Ltd (Bicester, Oxon, UK), or were bred in our own animal 
facility in The Western Infirmary, Glasgow. The following strains were used; 
PVG(RTlc), DA(RTla), PVG(RTlu) & PVG R8 (Laboratory report, 1979; 
Butcher & Howard, 1979). The MHC haplotype of the rats used in the 
experiments is shown in Table 1.
Male rats (8-16 week old), weighing 250-300g, were used throughout.
All animals were kept in the animal facility of the University Department 
of Surgery, Western Infirmary, Glasgow. They were fed with standard rat diet and 
water.
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Table 1. MHC haplotypes of PVG congenic 
and recombinant rat strains.
Rat Strain A
RT1
B
Regions
D C
PVG RT1C c c c c
DA RT1a a a a a
PVG R8 a u u u
PVG RT1u u u u u
* PVG R8 and PVG RT1u differ only a t the classical class I MHC locus 
They are otherwise genetically identical, including mH antigens.
** RT1c & RT1u have fully disparate MHC antigens but common mH antigens
*** DA RT1a & PVG RT1u have no common histocompatibility antigens
2:2 Surgical Procedures
2:2.1 Cardiac Transplantation
A heterotopic cardiac transplant to the intra-abdominal great vessels, as 
described by Ono & Lindsey (1969), was employed throughout the experiments 
described in this thesis.
Both donor and recipient rats were anaesthetised with 5% halothane and 
oxygen, and were then given an intra-peritoneal injection of 0.8-1.2 mis of 7.5% 
chloral hydrate in saline, dependent on their size. Towards the end of the 
experimental work presented in this thesis the anaesthetic technique was changed, 
on the advice of the supervising vet, to continuous halothane and oxygen 
delivered via a Fluovac system.
The rats were then shaved and the abdominal skin cleaned with 
chlorhexidine in alcohol.
The donor rat abdomen was then opened through a midline incision and 
the intestines swept cranially to expose the infra-renal inferior vena cava (IVC). 
300 units of heparin were then injected into the IVC and, after two minutes, the 
infra-renal IVC and aorta were cut and the rat exsanguinated. The thorax was then 
opened with scissors and the diaphragm divided. The donor heart was stopped 
with a combination of topical ice and cold saline. The IVC was mobilised and tied 
with 4-0 silk, just as it entered the heart. The thymus was then excised, exposing 
the vessels above the heart. The right superior vena cava was tied with 4-0 silk as 
it entered the heart, and the left superior vena cava was then mobilised and tied 
close to the heart, and divided. Next, the pulmonary artery and aorta were freed 
and divided, (Figure 2.1.1) care being taken to leave them long enough to allow
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Figure 2.1.1 Heterotopic cardiac transplantation in the rat.
*** Donor aorta is being divided following ligation of the right and left 
superior vena cavae and inferior vena cava. Donor pulmonary artery is 
also divided and the remaining pulmonary vessels are tied. These 
attachments are then cut, as are the superior and inferior vena cavae, 
allowing the donor heart to be lifted free.
the later anastomosis. The right superior vena cava and the inferior vena cava 
were then cut, distal to their ties. The remaining pulmonary vessels were then 
caught by a 4-0 tie, placed around the heart, carefully avoiding the delicate atria. 
The donor heart was then removed, by cutting on the donor side of this final tie, 
and placed in a petri dish of cold saline, which was kept on crushed ice. The heart 
was gently squeezed to expel any remaining blood and returned to the ice.
The recipient rat was taped out on a heated plate and it’s abdomen opened 
through a midline incision. The intestines were swept cranially and wrapped in a 
moist, saline swab. The infra-renal IVC and aorta were then dissected out and any 
venous or arterial branches were tied twice, with 8-0 silk, and divided. Once the 
major vessels were mobilised, great care was taken to identify and tie any lumbar 
vessels which entered behind the proposed site of the vascular anastomoses. The 
vessels were now ready to receive the graft (Figure 2.1.2). Occlusive vascular 
clamps were applied to the major vessels, immediately below the renal vessels 
and just above the bifurcation of the aorta, allowing as much vessel length as 
possible for the site of anastomosis. A puncture was made in both vessels with a 
fine needle and extended with scissors to form an arteriotomy and a venotomy of 
a size comparable to the donor aorta and pulmonary artery. The heated plate under 
the recipient was now switched off. The donor heart was removed from the cold 
saline and the aorta was anastomosed, end-to-side, to the recipient aorta, using a 
continuous 9-0 ethilon suture (Ethicon Ltd.) The donor pulmonary artery was then 
anastomosed, end-to-side, to the recipient inferior vena cava using the same suture 
(Figure 2.1.3).
Following completion of the anastomoses, the distal, and then the 
proximal, vascular clamps were released, briefly, and re-applied. Any bleeding 
points were controlled with small pieces of Spongistan. The distal and proximal
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Figure 2.1.2 Heterotopic cardiac transplantation in the rat.
*** Recipient IVC and abdominal aorta are visualised and prepared, below 
the renal vessels. Any branches are tied with 8-0 silk and divided. The 
abdominal contents are kept moist under a saline swab.
Figure 2.1.3 Heterotopic cardiac transplantation in the rat.
*** End-to-side anastomosis is performed between donor aorta and 
recipient aorta, using 9-0 nylon suture. The donor pulmonary artery is then 
anastomosed in a similar fashion to the recipient IVC.
vascular clamps were then removed and blood allowed to circulate through the 
graft.
The heart was observed until it had started beating normally and then the 
intestines were replaced, around the graft (Figure 2.1.4), and the abdomen closed 
in two layers, with continuous 3-0 cat gut suture (Ethicon Ltd.). The cold 
ischaemic time of the heart graft was approximately 20 minutes.
The viability of the heart grafts was assessed by daily palpation through 
the abdominal wall. Rejection was deemed to have occurred when the pulsation of 
the graft could no longer be felt by palpation of the abdominal wall. In doubtful 
cases the heart was examined by laparotomy and, if any pulsation was detected, 
the wound was closed and the rat woken up, to be re-assessed the following day.
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Figure 2.1.4 Heterotopic cardiac transplantation in the rat.
*** The abdominal viscera are placed around the functioning heterotopic 
heart graft prior to closure of the abdominal incision. The pulsating heart 
can then be easily palpated through the abdominal wall.
2:3 Cells and tissues
All procedures with cells were performed in DAB containing either 2% 
foetal calf serum (DAB/FCS) or 0.2% bovine serum albumin (DAB/BSA).
2:3.1 Lymph node cells
Cervical and mesenteric lymph nodes were removed from rats, following 
cervical dislocation. The nodes were pooled, chopped with a scalpel and forced 
through a fine stainless steel mesh with a syringe plunger, in DAB/FCS or 
DAB/BSA. The cells were washed two or three times, in DAB/FCS, and dead cell 
aggregates removed with a pasteur pipette.
2:3.2 Spleen cells
Splenectomy was performed following cervical dislocation. The spleens 
were teased apart with sterile forceps in DAB/FCS or DAB/BSA. The cells were 
washed and dead cells removed. Erythrocytes were removed by hypotonic lysis 
using 5 mis distiled water followed by 5 mis double strength saline. Splenocytes 
were washed three more times before use.
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2:3.3 Concanavalin A stimulated lymphoblasts
51 Chromium (^C r) labelled Concanavalin A (ConA)-stimulated 
lymphoblasts were used as target cells in lymphocyte mediated cytotoxicity 
assays. Lymphocytes were prepared from rat spleens, as described above, and 
adjusted to a concentration of 2-2.5 xlO^ cells/ml in RPMI containing 10% FCS, 
glutamine, penicillin, streptomycin and 2 x 10"  ^ M 2-mercapto-ethanol (BDH 
Ltd.). 10 mis cell suspensions were incubated in tissue culture flasks with 5 |ig/ml 
Concanavalin A (Sigma Chemical Co.) for 72 hours at 37°C in 5% CO2 in air. 
Lymphoblasts were washed once and counted before use.
2:4 Monoclonal antibodies
For the in vivo depletion of T cell subsets, the following monoclonal 
antibodies were used:
a) MRC 0X8 - an IgGj antibody specific for CD8+ 
cytotoxic/suppressor T cells and the majority of natural killer cells 
[Gillman, Rosenberg & Feldman (1982), Dallman et al (1982), 
Cantrell, Robins, Brooks et al (1982)].
b) MRC 0X35 & MRC 0X38 - both anti-CD4+ T cell monoclonal 
antibodies of the IgG2a subclass, which bind to different epitopes of 
the CD4 molecule, and do not crossblock each others binding (Jeffries, 
Green & Williams, 1985: Roser, 1989)
c) MRC 0X21 - mouse mAb against human C3b inactivator, which 
was used as a negative control (Hsiung, Barclay, Brandon et al 1982).
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The antibodies were produced in mouse ascites, following intra-peritoneal 
injection of appropriate myeloma hybridoma cells (European Collection of 
Animal Cell Cultures, Porton Down, Salisbury, Wiltshire), into Pristane (Sigma 
Chemicals) primed (DBA/2 x BALB/c)Fl mice (Harlan Olac Ltd.). The 
immunoglobulin content of ascites was quantified using anti-mouse IgGj 
immunodiffusion plates and known mouse Ig standards (Serotec Ltd.). Antibodies 
were diluted in PBS, as required, and stored at -20°C.
They were administered to the experimental animals by intraperitoneal 
injection.
In addition, the following mouse mAbs were used to label rat leukocytes: 
MRC 0X1 (leukocyte common antigen [Sunderland, McMaster & 
williams, 1979]);
MRC 0X18 and MRC 0X6, which recognise polymorphic 
determinants of MHC class I and class II antigens, respectively 
(Fukomoto, McMaster & Williams, 1982);
EDI, which labels most tissue macrophages, monocytes and dendritic 
cells (Dijkstra, Dopp, Joling et al, 1985);
R73, which recognises a constant determinant of the rat TCR-a/p 
(Hunig, Wallny, Hartley et al, 1989);
W3/25, which labels CD4+ T helper lymphocytes and some 
macrophages (Mason, Arthur, Dallman et al, 1983).
The above were obtained from Serotec Ltd., Oxford, U.K.
63
2:5 Histology
2:5.1 Cryostat sections
Cardiac cross-sections were embedded in OCT compound (Tissue-Tek, 
BDH Ltd.), snap frozen in liquid nitrogen and 5| l l  cryostat sections were cut at - 
20°C onto gelatinised multispot slides (C.A.Hendley, Essex).
2:5.2 Immunoperoxidase staining
Sections were fixed in acetone (BDH, Ltd.) at room temperature for 10 
minutes, then washed in DAB. Excess moisture was dried from each section and 
50jil of primary monoclonal antibody, appropriately diluted, were applied to each 
section. Slides were incubated for 45 minutes at RT in an humidified chamber, 
then washed three times in DAB. The secondary antibody was applied, consisting 
of peroxidase-conjugated rabbit anti-mouse Ig (Dako Ltd.) containing 10% 
normal rat serum to absorb out any cross-reacting activity.
After 30 minutes incubation at RT, the slides were washed three times and 
the substrate was added [0.6 mg/ml 3,3-diaminobenzidine tetrahydrochloride 
(Sigma Chemical Co.) plus 0.01% hydrogen peroxide, for 5 minutes]. The 
sections were then lightly stained in Harris's haematoxylin, were dehydrated and 
cleared in alcohols and xylene, and were mounted in DPX (BDH Ltd.).
2:5.3 Morphometric analysis of cellular infiltrate
The area of each immunoperoxidase-labelled tissue section infiltrated by 
leukocytes of a particular phenotype was determined by morphometric analysis 
using the point counting technique (Aheme & Dunnill, 1982; McWhinnie, 
Thompson, Taylor et al, 1986). Sections were examined at a magnification of 400
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in the presence of a microscope eyepiece graticule engraved with a squared grid 
bearing either 121 intersections (1mm apart) or 745 intersections (0.5mm apart). 
For each high powered field, the number of positively stained cells superimposed 
by an intersection was counted, and the area of the field occupied by cells of a 
particular phenotype was calculated as:
% area of infiltrate= no. -t-ve grid intersections x 100 
total no. grid intersections 
Ten consecutive fields were counted for each section, so that for all sections the 
total number of points observed was well in excess of that required to maintain the 
accuracy of the point counting technique (Aheme & Dunnill, 1982)
2:6 Serum antibody titres
To determine allospecific serum antibody titres, the rats were bled from 
the tail on selected days following transplantation. The samples were allowed to 
clot, and were spun down. The serum was heat inactivated in a water bath at 56°C 
for 30 minutes and then centrifuged briefly to remove protein aggregates. It was 
then serially diluted in RPMI/5%FCS/20mM Hepes and mixed with ^ C r-la b e lled  
splenocytes of both donor and third-party strain rats.
After incubating at RT for 30 minutes, freshly reconstituted guinea pig 
complement (Sera-Lab, Sussex), diluted 1 in 5, was added, and the cells were 
incubated for one hour at 37°C. The ^ C r  released into the supernatant was 
counted in a gamma counter and titration curves of % ^ C r  release against serum 
dilution were made for each serum sample.
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2:7 Cell mediated cytotoxicity
2:7.1 Effector cells
Splenocytes, for use as effector cells in cell mediated cytotoxicity assays, 
were obtained as described in section 2.3.2, and were resuspended in 
RPMI/5%FCS/20mM Hepes.
2:7.2 ^Chromium release assay
A standard ^ ^  Cr-release assay based on the experiments of Brunner et al 
(1968) was used. Target cells were labelled by incubation with 5 MBq ^ C r- 
sodium chromate for 90 minutes at 37°C with frequent mixing. Cells were washed 
five times and then resuspended in medium.
Serial twofold dilutions of effector cells were made, to give effector:target 
cell ratios of 100:1, 50:1, 25:1, 12.5:1, 6:1 and 3:1.
Equal volumes (75p.l) of effector and target cells were mixed in wells of 
96 V-well microtitre plates (Sterilin, Teddington) so that each well contained 
5xl03 or 104 target cells, and each cell combination was set up in triplicate or 
quadruplicate. Spontaneous release from targets was determined using medium 
instead of effector cells, and maximum release obtained by adding 10% Triton X 
(BDH) instead of effectors. The plates were centrifuged briefly then incubated for 
6 hours at 37°C in 5% CO2 in air. From each well, 75ju.l supernatant was taken 
and the amount of released isotope was determined by a Compugamma counter 
(LKB, London). The amount of isotope released as a result of effector cell activity 
was calculated as follows:
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% cytotoxicity= (experimental-spontaneous releaselx 100 
(maximum-spontaneous release)
2:8 Cell preparation and fluorescence analysis.
Single cell suspensions of lymph nodes and spleen were prepared as 
described previously (Bolton et al, 1989). PBL were separated by centrifugation 
of heparinised whole blood over 75% iso-osmolar Percoll (Sigma Ltd., Poole, 
UK). For single colour fluorescence analysis, cells were incubated with the 
appropriate mAb for 1 hr at 4°C, washed twice in DAB/BSA, and incubated for 1 
hr at 4°C with FITC-conjugated F(ab)2 mbbit anti-mouse Ig (Dako Ltd., High 
Wycombe,UK) containing 10% normal rat serum to prevent cross-reaction of the 
antibody with rat Ig.
For two-colour fluorescence analysis, the first stage was as described 
above. For the second stage, unbound sites of the second antibody were blocked 
with MRC 0X21 (mouse anti-human C3b) and the cells were incubated for 30 
min at 4°C with biotinylated W3/25 or biotinylated MRC 0X8 (a gift from Dr. E. 
Bell, Department of Immunology, University of Manchester, UK) followed by a 
phycoerythrin-streptavidin complex (Becton Dickinson, Mountain View, CA). 
Cells were washed twice in DAB/BSA to remove excess antibodies. The labelled 
cells were analyzed on a FACScan flow cytometer (Becton Dickinson).
2:9 Statistical Analysis
All of the statistical analyses in this thesis were performed using the Mann- 
Whitney Test.
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CHAPTER THREE.
Unmodified rejection of an MHC class I disparate graft
68
3:1 The Unmodified Rejection of an Isolated Class I Disparate Cardiac 
Allograft.
As has been mentioned before, there has been considerable variation in the 
reported literature regarding the cellular and humoral requirements for allograft 
rejection in animal models. Many of the apparently contradictory findings of 
different laboratories may be attributable to variation of species, or strain 
combinations used.
In addition, it has been speculated that the type of allograft itself may have 
an effect on the mechanism of its rejection. In particular, much of the early 
experimental work on allograft rejection was performed using skin grafts, and it is 
now recognised that the mechanism of rejection is different when the graft is a 
primarily vascularised organ graft.
Previous work in this laboratory, aimed at elucidating the cellular 
requirements for renal allograft rejection, produced some interesting data to 
suggest a possible role for alloantibody in the acute rejection of an isolated class I 
disparate renal allograft, which challenged the widely held belief that rejection of 
such a graft is mediated by CD8+ CTL (Gracie et al, 1990).
We have established a model of acute rejection of an isolated class I 
cardiac allograft (PVG R8—PVG RTlu) in the rat, to allow examination of the 
hypothesis that cytotoxic alloantibody is an important effector mechanism in the 
acute rejection of such a graft.
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Before considering the evidence in favour of alloantibody, the cellular and 
humoral events taking place during the unmodified rejection of a class I disparate 
graft will be examined.
3:2 Cellular infiltrate in unmodified rejection.
PVG R8 hearts were grafted heterotopically into PVG RTlu recipients, as 
described in Chapter 2. The condition of the grafts was assessed by daily 
palpation, through the abdominal wall, by the author. The hearts were deemed to 
have been rejected when there was no palpable pulsation, and it was noted during 
this work that there was a consistently rapid cessation of contraction of the graft, 
rather than a slow deterioration over several days.
In this strain combination, the mean survival time (MST) of the grafts was 
6.5 days
To assess the cellular infiltrate of the rejecting grafts, recipient animals 
were sacrificed on days 1,3,5 & 7 post-transplant, and their grafts were snap 
frozen and sectioned to allow direct staining, and indirect immunoperoxidase 
staining, to be carried out, as described in Chapter 2.
In keeping with similar experiments performed on rat renal allografts in 
this laboratory, it was found that there was a progressive cellular infiltration of the 
graft, between day 3 and day 5, and after this there was such extensive damage to 
the graft that useful analysis was not possible.
Using a panel of mouse anti-rat mAbs, day 5 heart grafts from both 
syngeneic controls and unmodified, rejecting animals, were sectioned and stained 
by indirect immunoperoxidase techniques. The mAb used, and their targets are 
listed in Chapter 2 (2.4).
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The effects of the transplant operation itself were examined by comparing 
syngeneic grafts (R8—R8) with naive R8 hearts. The syngeneic graft was found 
to be almost identical to the normal R8 heart in this experiment. In both there was 
a moderate expression of class II MHC, which did not alter as a result of 
transplantation. The expression of class I was less, in both groups but, once again, 
was unaffected by the operative procedure. The morphology of the cellular 
infiltrate of the hearts was comparable. Both showed very light staining with OX 
1 indicating the presence of a few leukocytes, but had no significant staining for 
TCR or for either CD4 or CD8. A slightly positive staining for ED 1 showed that 
those leukocytes present, were macrophages. When the unmodified rejecting 
grafts (day 5) were compared with the syngeneic grafts it was found that there was 
a significant increase in the expression of class II MHC in the rejecting graft. 
There was also an increase in class I MHC expression in the rejecting graft but the 
expression of class I remained weaker than that of class II.
With respect to the cellular infiltrate, the R8 heart being rejected by the 
RTlu rat showed an increase in the number of leukocytes (OX 1) in the graft as 
compared to the syngeneic R8 graft. There was a slight increase in staining for 
TCR (R 73), with an associated increase in CD8 positivity, but CD4 remained 
negative. The most striking appearance in the rejecting graft was the increase in 
the number of macrophages infiltrating the graft.
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3:3 Alloantibody production in unmodified rejection.
It has previously been shown that, in a model of renal transplantation in 
the rat, acute rejection of the graft is associated with the production of high levels 
of specific alloantibody (Gracie et al, 1990). This finding leads to the hypothesis 
that alloantibody may act as an effector mechanism of such an acute rejection 
response. This remains controversial, however, with Lowry & Clarke Forbes 
(1984) stating conclusively that alloantibody and B cells were not required for the 
rejection of a cardiac graft in a rat model. They found that an irradiated Lewis rat 
could reject a heart from an irradiated Wistar-Furth rat when the recipient was 
reconstituted with primed splenocytes, from which B cells had been removed and 
which lacked a demonstrable alloantibody response. They reported that, in the 
absence of antibody, the histological microvascular damage was the same as that 
seen in unmodified rejection.
We determined the level of alloantibody produced by the RTlu rat strain, 
against an isolated class I disparate cardiac allograft of the R8 strain, by 
measuring the amount of ^ C r  release from ^ C r  labelled R8 blasts which had 
been combined with serum from RTlu rats which were rejecting R8 hearts. The 
results are shown in Figure 3.1.
It was found that there was a steady increase in alloantibody production 
from day 3 which was maximal on day 15, when the final test sera were taken.
The production of alloantibody is not surprising, in itself. Of greater 
interest, is whether this antibody is central to the acute rejection of the graft.
It is now generally accepted that the primary target of the rejection 
response against a vascularised allograft is the microvasculature of the graft, and
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Figure 3.1 A lloantibody lev e ls  in unm odified rejection
100
80
60
40
20
0
N 1/1281/16 1/32 1/64
reciprocal dilutions
Specific alloantibody produced against a  c lass  I d isparate  graft 
w as determ ined by m easuring the % re lease  of 51 Cr from labelled 
R8 lym phoblasts mixed with reciprocal dilutions of RT1u rejecting serum .
* Significant levels of donor-specific alloantibody were detected 
from day 3 onwards.
more specifically, the vascular endothelium (Forbes, Guttmann, Gomersall et al, 
1983; Adams et al, 1989; Bishop et al, 1989).
If it is being proposed that alloantibody may play a significant role as an 
effector mechanism in this response it is important to demonstrate the ability of 
alloantibody to cause endothelial cell damage.
To explore the cytotoxic properties of the alloantibody contained in 
rejecting serum, the ability of day 7 and day 10 rejecting serum to specifically 
lyse in vitro cultured monolayers of R8 neonatal heart endothelial cells, which had 
been prepared as described in Chapter 2., was examined. During these 
experiments, either guinea pig complement or RTlu rat serum alone was used as a 
source of complement. PVG RTlc endothelial cells were used as a third-party 
control.
It was found that when the R8 cells had been cultured in the presence of 
IFN-y, the addition of day 7 or day 10 RTlu rejecting serum resulted in in vitro 
complement dependent cytotoxicity with endothelial cell lysis (Figure 3.2).
Contrary to previous reports of the deficiencies of the rat complement 
system in different rat strains (French, 1972; Oluwole, Tezuka, Wasfie et al, 
1989), RTlu serum proved to be an adequate source of complement to allow cell 
lysis to occur. The specificity of the CDC reaction was shown by the fact that the 
RTlu rejecting serum, which was effective against R8 endothelial cells, was 
unable to lyse third-party endothelial cells cultured from neonatal PVG RTlc rats 
in the presence of IFN-y. It was also found that if the R8 neonatal endothelial cells 
were cultured without IFN-y, the addition of day 7 or day 10 rejecting serum, in 
the presence of either guinea pig complement or RTlu serum, did not result in a 
CDC response and there was no lysis of the endothelial cells.
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Figure 3.2 CDC activity of rejecting serum v s R8 
and PVG endothelial ce lls  cultured in 
vitro with gamma IFN
1
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* The only source of complement in this experiment w as RT1 u serum. 
Pooled sera  from RT1 u rats which had been transplanted with R8 hearts 
were tested  for CDC activity against R8 and PVG neonatal cardiac 
endothelial cells, cultured in vitro with gam m a IFN.
** The rejecting serum was specifically cytotoxic to donor-type (R8) 
endothelial cells.
*** When cultured without gam m a IFN neither endothelial cell type 
was lysed by the rejecting serum.
The fact that co-culture with IFN-y was required before the endothelial 
cells were susceptible to CDC with rejecting serum, supports the concept of the 
important role of cytokines in activating vascular endothelial cells and increasing 
their expression of class I and especially class II MHC antigens (Halloran & 
Madrenas, 1990). It is by recognition of, and binding to these surface antigens that 
alloantibody is able to initiate its cytotoxic effects. The absence of any non­
specific effector cells from the transferred rejecting serum shows that the specific 
cytotoxicity in this in vitro experiment is as a result of CDC, and not an example 
of ADCC.
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3:4 Discussion.
The acute rejection of a vascularised cardiac allograft is a predictable and 
consistent event, unless the recipient is immunosuppressed. The speed with which 
the heart is rejected is dependent upon the strain combination of the experimental 
animals used, and the MHC disparity between the donor and the recipient.
Complete disparity for both MHC and mH antigens results in rapid 
rejection of a rat heart graft in 6-8 days but, in certain strain combinations, an 
isolated RT1A subregion (class I) disparate graft survives indefinitely (Guttmann, 
Forbes, Fuks et al, 1985; Klempnauer, Steiniger, Wonigeit et al, 1985) whereas 
RT1B (class II) disparate grafts are rapidly rejected. However, use of the high 
responder PVG RTlu haplotype to PVG RTla class I antigens has been shown to 
result in rapid rejection of a cardiac allograft (Lowry et al, 1985) and this has been 
confirmed by the results of the experiments described in this thesis, with 
unmodified RTlu recipients rejecting R8 hearts in 7 days.
The histological and immunohistological findings that are reported here 
are similar to those previously reported, using a similar model (Clarke Forbes et 
al, 1988), with a progressive infiltration of the rejecting graft by mononuclear 
cells, the majority of which are macrophages. Those few T cells which were found 
in the rejecting grafts were almost exclusively CD8+, but this fact, in itself, is not 
significant evidence that the CTL is crucial to the rejection of this particular graft. 
It is , if anything, surprising, in the light of the accepted MHC restriction of CD4+ 
and CD8+ T cells, that a rejecting, class I disparate graft is not heavily infiltrated 
with CD8+ cells. This finding is consistent with previous experimental results 
from this laboratory, when it was found that rejecting, class I disparate kidney 
grafts had a similar pattern of cellular infiltration as class I disparate grafts which 
were not being rejected because their recipients were "low responders". The
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cellular infiltrate consisted predominantly of macrophages, and complete 
depletion of CD8+ cells, by mAb OX 8, had no effect on the makeup of the 
infiltrate, nor on the survival time of the grafts which were all rejected by first-set 
rejection kinetics (Gracie et al, 1991). This work brings into question the widely 
accepted belief that the CD8+ T cell is an absolute requirement for the rejection of 
an isolated class I disparate allograft (Lowry et al, 1985), and, furthermore, the 
associated finding of markedly elevated titres of specific alloantibody in the 
rejecting animals serum has stimulated closer examination of the role played by 
this antibody, and by the T cell subsets, in the rejection of a cardiac graft of the 
same MHC disparity, by our laboratory.
It was decided to approach the investigation of the contribution of each T 
cell subset in the acute rejection of a class I disparate cardiac allograft in the rat by 
selectively depleting them, individually, in vivo, using mouse anti-rat monoclonal 
antibodies, which were obtained from mouse ascites, as described in Chapter 2.
The results of these experiments form the next two chapters of this thesis.
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CHAPTER FOUR 
The role of CD8+ T cells in the rejection of an MHC class I disparate graft
77
4:1 The CD8+ T cell in the rejection of a class I disparate graft.
The fact that the CD8+ T cell is restricted to recognition of, and interaction 
with, class I MHC and not class II, makes it seem a logical conclusion that it 
could be the predominant effector mechanism in the rejection of an allograft 
which differs from the recipient only at the classical class I MHC subregion. 
Indeed, there are many workers with an interest in this field who are convinced 
that this is the case. It is certainly true that specific CTLs have been shown to be 
present in both human and animal rejecting allografts (von Wiliebrand & Hayry, 
1978; Hayry, von Wiliebrand & Soots, 1979), but although most reviewers 
propose that the CTL is the likeliest effector cell in allograft rejection, the crucial 
importance of cytokine help, provided by CD4+ T helper cells, in the activation of 
these specific cytotoxic T cells is stressed (Bradley et al, 1985; Steinmuller, 1985; 
Mason & Morris, 1986; Hall, 1991).
It has also been shown, however, that unprimed Lyt-2+ (CD8+) cells can 
respond to class I antigen, in vivo, without help from CD4+ T cells (Sprent, 
Schaefer, Lo et al, 1986) but this may be explained by the fact that in certain 
murine strains the CD8+ T cells have the ability to produce their own 11-2, which 
is not the case in the rat model(Sprent, Schaefer, Lo et al 1986; Mizuochi, Ono, 
Malek et al, 1986).
Most recently, in an attempt to explain why mice which had been depleted 
of CD8+ cells by mAb were still able to reject a class I disparate skin graft, 
Rosenberg and co-workers have proposed the existence of a unique subset of 
CD8+ cells which are not only resistant to depletion by anti-CD8 mAb but are, in 
fact, activated by the monoclonal antibody (Rosenberg, Munitz, Maniero et al, 
1991). This new concept will require further examination to determine its validity.
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In the light of the surprising finding, in our laboratory, that complete 
depletion of CD8+ cells had no protective effect on a class I disparate renal graft 
in a rat model, the experiment has been repeated, in the same high responder 
strain combination, using a heterotopic heart graft
4:2 Depletion of CD8+ cells by 0X8 monoclonal antibody.
Recipient rats, of the RTlu strain, were treated with OX 8 mAb (2mg/ml), 
given by intraperitoneal injection in the following doses:
1.5ml on the day before transplant (D -1)
1.0ml on the day of transplant (D 0)
0.5ml on the third day post-transplant (D 3)
0.5ml on the sixth day post-transplant (D 6)
0.5ml on the ninth day post-transplant (D 9)
These doses have previously been shown to cause effective elimination of CD8+ 
cells (Gracie et al, 1990). On Day 0 the RTlu rats were transplanted with an R8 
heart. The heterotopic, intra-abdominal grafts were then palpated daily, in the 
standard fashion, to determine the time of rejection. As can be seen in Table 2 , 
there was no difference in the graft survival time between those recipients which 
had received the anti-CD8 mAb (mean 6.8 days) and the unmodified recipients 
which rejected their grafts in the expected manner (mean 6.7 days).
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Table 2. Graft Survival Time (GST) in unmodified 
rejection of a c la ss  I disparate graft 
and following anti-CD8 mAb treatment.
Strain
combination mAb GST (days) Mean GST (days)
R 8-^R T 1u 6,6,6,6,7,7,7,8 6.8 
0X8 6,6,6,7,7,7,7,7 6.8R 8-^R T 1u
□Treatment with anti-CD8 mAb 0X8 had no effect on the rejection 
of this class I disparate heart graft.
4:3 Efficiency of 0X8 mAb.
With the findings of this experiment in mind, it is of obvious importance 
to determine whether 0X8 is effective in its proposed role as a depleter of CD8+ 
cells as, if this were not the case, it would not be possible to draw any valid 
conclusions from these data.
Three techniques were employed to investigate the extent of CD8+ cell 
depletion, and these were:
a) Two-colour Fluorescence Activated Cell Sorter (FACS)
scanning;
b) Indirect immunoperoxidase histology
c) Attempted in vitro generation of specific CTLs.
4:3.1 FACS analysis in 0X8 treated group.
The result of the FACS analysis in the rats which had received 0X8 is 
shown in Figure 4.1.
The mAb R73 was used to label T cells, while the CD8 molecule was 
labelled by 0X8.
In the control animal, the normal distribution of cells in a FACS result can 
be seen. Following anti-CD8 mAb treatment, there has been an obvious and 
complete depletion of CD8+ cells, including both T cells and non-T cells alike. 
Furthermore, it can be clearly seen that all the remaining T cells in these rats are 
CD4+, and these have not been affected by the anti-CD8 depletion therapy. This 
finding demonstrates that 0X8 mAb treatment has resulted in true depletion of the 
CD8+ cell population, and not simply modulation of the surface antigen.
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Figure 4.1 FACS analysis of peripheral blood leukocytes in anti-CD8 
treated animals and controls.
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* Controls were treated with OX21
** There has been complete depletion of the CD8+ cells following 0X8 
mAb treatment.
*** Treatment with 0X21 (anti-human C3) has had no effect on the PBLs.
4:3.2 Immunoperoxidase histology in 0X8 treated group.
This technique is described in detail in Chapter 2.
Figure 4.2 shows peroxidase-stained sections of day 5 heart grafts taken 
from an unmodified, rejecting heart, and a rejecting heart from an anti-CD8 
treated animal, respectively. Once again, it is clear that treatment with 0X8 has 
resulted in the complete depletion of CD8+ cells from the graft, confirming the 
FACS result of elimination of CD8+ cells from the peripheral blood and lymph 
nodes following mAb administration.
4:3.3 Generation of cytotoxic T cells.
To assess the effect of anti-CD8 mAb treatment on the function of CTLs in 
the recipient animals, cytotoxic T cells were generated, in vitro, from RTlu lymph 
node cells of both control (0X21), and 0X8 treated animals, by co-culture for 5 
days with irradiated RTla stimulators. The cytotoxicity of the cells was then 
determined by measuring the % specific release when the cells were combined 
with ^ C r  labelled R8 lymphoblasts.
Figure 4.3 shows that there was a high level of specific cytotoxicity 
against the donor-strain lymphoblasts in the control group, and that this activity 
was completely abrogated in the animals which had received anti-CD8 treatment.
Taken in combination, the results of the FACS analysis; the 
immunoperoxidase histology, and the in vitro cytotoxicity assay, have clearly 
demonstrated that 0X8 mAb treatment is extremely effective in, both 
phenotypically and functionally, depleting CD8+ cells from recipient animals.
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Figure 4.2 Immunohistological assessment of CD8+ T cell depletion by 
anti-CD8 mAb.
t
I
U
a) Unmodified control R8 —  RT1U (day 5)
b) R8 RT1U + 0X 8 (day 5)
* Both sections have been stained by an indirect immunoperoxidase 
technique for CD8+ cells
* The CD8+ cells seen in the unmodified control rejecting graft have been 
completely removed by the 0X 8 treatment.
The class I disparate graft in b) is being rejected in the absence of 
CD8+ cells.
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Figure 4.3 The effect of in vivo anti-CD8 mAb 
treatment on generation of c la ss  I 
specific cytotoxic T cells in vitro.
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* Cytotoxic T cells w ere generated  from RT1 u lymph node cells 
(control or anti-CD8 treated) by culture for 5 days with irradiated 
RT1 a stimulators. Cytotoxicity w as determined against 51 Cr labelled 
R8 lymphoblasts.
** The control mAb w as OX21.
*** Treatment with OX8 has prevented the generation of class l-specific 
cytotoxic T cells.
4:4 Discussion.
The results of the experiments have shown that, in this strain combination, 
an isolated class I disparate heart graft has been rejected, with first-set kinetics, in 
the complete absence of CD8+ T cells.
This directly contradicts the findings of Lowry et al (1985) who concluded 
that the cytotoxic, CD8+, T cell was crucial in the rejection of a heart graft 
bearing such an MHC incompatibility, albeit in a different strain combination 
[irradiated (PVGxWF)Fl recipients of irradiated PVG-RTlrl grafts]. In addition, 
it brings into question the commonly held belief that the CTL, more than any 
other, is the predominant effector mechanism in organ allograft rejection.
Unless the recent hypothesis of an anti-CD8 mAb resistant, CD8+ CTL, 
put forward by Rosenberg et al (1991) is to be believed, it is apparent from these 
results that it is perfectly possible for a class I disparate graft to be rejected 
without any contribution from the CTL subset. It obviously cannot be assumed 
from these results, that the CTL does not play a significant role in the rejection of 
other allografts, with different MHC disparities, but it can be stated, with some 
certainty, that, in this model, an allograft is being rejected bv some mechanism 
other than bv cvtotoxic T cells.
The fact that this particular class I disparate graft has been rejected, 
without CD8+ CTLs, raises two important questions:
1. How is the foreign class I MHC recognised by the recipient, 
given the MHC restrictions of CD4+ and CD8+ T cells?
2. What is the effector mechanism which is initiating the rejection 
of this particular graft?
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There is increasing evidence to suggest that foreign, class I MHC antigen 
can be recognised by CD4+ T cells following processing of the antigen and 
presentation to the T cell in the context of self class II MHC (Golding & Singer, 
1984; Rock, Barnes, Germain et al, 1983; Cheng, Madrigal, Parham, 1990). This 
explanation would account for the recognition of this graft as foreign, if the class I 
MHC antigens, which by convention are only recognised by CD8+ T cells, are 
being processed and presented to CD4+ T cells, in the context of self class II.
As will become apparent when the results of experimental depletion of 
CD4+ T cells are examined, it appears that there is a direct correlation between 
the production of specific alloantibody against a graft, and the acute rejection of 
that graft. The possibility that this alloantibody could be the initiator of the 
immunological rejection response mounted against a class I disparate graft will be 
explored later in this thesis.
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CHAPTER FIVE
The role of CD4+ T cells and of specific, cytotoxic alloantibody in the 
rejection of an MHC class I disparate graft
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5:1 The CD4+ T cell in the rejection of a class I disparate graft.
Having established, in both the kidney and heart transplant models in the 
rat, that complete depletion of the CD8+ T cell subset by 0X8 mAb treatment, 
had no effect on the survival time of a class I disparate graft, attention was turned 
to the contribution of the CD4+ T cell subset to the rejection of a heterotopic heart 
graft with the same MHC antigen incompatibility.
Since the work of Loveland & McKenzie and Dallman & Mason, both of 
whom described graft rejection in irradiated animal models following the 
administration of CD8“, but not CD4" T cells, the crucial role of the CD4+ T cell 
in allograft rejection has been increasingly emphasised. In major reviews of the 
current literature both Mason & Morris (1986) and Hall (1991) stress the 
importance of T cell "help" for the activation and initiation of several 
mechanisms, both cellular and humoral, which may contribute to the rejection of 
various allografts, in both the experimental and clinical setting. This help comes 
in the form of lymphokines which are predominantly, but not exclusively, secreted 
by CD4+ T cells (Gajewski, Scott, Schell et al, 1989). The lymphokines II- 
2,3,4,5,6 & 10 are all produced, for the most part, by CD4+ T cells in the human 
and the rat, although it has been shown that in some strains of mouse CD8+ T 
cells produce substantial amounts of 11-2 (Sprent et al, 1986; Mizuochi et al, 
1986), which may account for the apparent importance of the CD8+ T cell in 
rejection experiments involving these particular strains.
Activated CD8+ T cells can secrete both IFN-y and TNF-p. However, the 
bulk of the evidence suggests that in most situations CD8+ T cells are dependent 
upon CD4+ T cells to become activated. Further subdivision of the CD4+ T cell 
subset has been suggested on the basis of lymphokine production. Two types of
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murine, CD4+ T cell clones have been developed with different lymphokine 
signatures:
T jjl, which produces 11-2, TNF-p and IFN-y but not 11-4,5 or 10, 
and
Tj|2, which produces 11-4,5 and 10, but not 11-2, TNF-p or IFN-y 
(Mossmann, Cherwinski, Bond et al, 1986).
It has been postulated that these different subgroups of Tjj cells may 
provide help for different effector mechanisms. It has also been shown that each 
Tjj subgroup has the ability to influence the growth and function of the other and, 
if the hypothesis above is correct, thereby influence the type of immune response 
which results (Fiorentino, Bond & Mossmann, 1989; Gajewski, Joyce & Fitch, 
1989). This is, however, an area which requires further investigation and 
clarification.
In an attempt to assess the relevance of the CD4+ T cell to the rejection of 
a class I allograft, in vivo depletion of CD4+ cells by monoclonal antibodies has 
been employed.
5:2 Effect of anti-CD4 mAb treatment on graft survival.
As with the previous experiment looking at the role of CD8+ T cells, the 
strain of the donor rat was PVG R8 while the recipient was the high responder 
PVG RTlu.
Heterotopic cardiac transplants were performed and the recipient rats were 
treated with the mixture of 0X35 and 0X38, both anti-CD4 monoclonal 
antibodies, as follows:
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0X35 (3mg/ml)
1.0ml on the day of transplant(D.O)
0.5ml on D. 1 
0.5ml on D.3 
0.5ml on D.6 
0.5ml on D.9 
0.5ml on D.12
0X38 (5mg/ml)
1.0ml on D.O 
0.5ml on D. 1 
0.5ml on D.3 
0.5ml on D.6 
0.5ml on D.9 
0.5ml on D.12
In contrast to the rats treated with anti-CD8 mAb, which rejected their 
grafts rapidly, there was a marked prolongation in the graft survival time 
following treatment with the anti-CD4 cocktail of 0X35 and 0X38. Of the 8 rats 
which received anti-CD4 mAb, 2 recipients rejected their grafts with only a few 
days delay at 12 and 14 days (5-7 days longer than unmodified rejection or in the 
anti-CD8 treated group), but the remaining 6 all had significantly prolonged graft 
survival times of 34, 57 & 73 days, and 3 rats which were sacrificed with 
functioning cardiac allografts 250 days following transplantation (Fig. 5.1.).
It is clear from these results, which have been consistently reproduced in 
subsequent experiments, that treatment with anti-CD4 monoclonal antibodies is an 
effective method of producing prolonged survival of a class I disparate graft in 
this "high responder" strain combination. This adds weight to the argument for a 
central role in allograft rejection for the CD4+ T cell, but it does not, in itself, 
provide any direct evidence as to the effector mechanism, or mechanisms, which 
are mediating the destruction of these allografts, other than to suggest that these 
mechanisms are under the control of CD4+ T cells. Equally, it does not exclude an
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Table 3. Graft Survival Time (GST) in unmodified 
rejection; anti-CD8 treatment,and 
anti-CD4 treatment.
Strain
combination mAb GST (days) Mean GST (days)
R 8-^R T 1u 6,6,6,6,7,7,7,8 6.8
R 8-^- RT1 u 0X8 6,6,6,7,7,7,7,7 6.8
R 8 - ^  RT1 u 0X35/38 12,14,34,57,73,>200, >200,>200
98.7
Mean graft survival time of this class I disparate heart graft 
has been significantly prolonged by targeting CD4+ T cells 
with mAb (p=0.0008)...but not by targeting CD8+ cells
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Figure 5.1 Ability of mAb treatment to prevent 
rejection of a class I disparate 
heart graft.
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- anti-CD8 treatm ent resulted in the sam e GST a s  controls.
- anti-CD4 treatment significantly prolonged GST.
Three hearts in this group were still beating 200 
days post transplant when the animals were sacrificed.
important role for CD8+ cells although clearly they are unable to cause rejection 
of class I disparate grafts autonomously.
5:3 FACS analysis following anti-CD4 treatment.
To assess the effectiveness of the mixture of 0X35 & 0X38 in depleting 
CD4+ T cells, lymph node cells (LNC) from treated rats were submitted to 2 
colour FACS analysis, and the results are shown in Figure 5.2. As before, the 
results from the treated rats are compared with unmodified control animals.
Knowing that treatment of these rats with this combination of monoclonal 
antibodies had been so effective in prolonging graft survival, it is perhaps 
surprising to find in the FACS analysis, that although there has certainly been a 
reduction in the number of CD4+ cells following treatment with 0X35 & 0X38, 
the numerical depletion has been nothing like as complete as that of the CD8+ 
cells by mAb 0X8.
Of greater interest than simple numerical depletion, however, is the effect 
of the anti-CD4 mAb treatment on the functional capability of the CD4+ T cell to 
provide help for the mediation of effector mechanisms of rejection.
5:4 Anti-CD4 treatment and alloantibody.
As it had already been demonstrated that this class I disparate graft was 
being rejected in the complete absence of CD8+ CTLs, and that 0X8 treatment 
had had no effect on the high levels of alloantibody which was generated, 
specifically, against the cardiac graft, it was of great interest to determine whether 
the prolonged graft survival obtained with anti-CD4 treatment was associated with 
any effect on the level of specific alloantibody produced by the recipient against 
its graft.
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Figure 5=2 FACS analysis of lymph node cells from anti-CD4 treated 
animals and controls.
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* Controls were treated with OX21
** 0X35/38 mAb treatment has depleted, but not eliminated, the CD4+ T 
cell population compared with the 0X21 treated controls. This CD4+ cell 
depletion is associated with significant prolongation of graft survival time.
As was the case with both the unmodified rats and those treated with anti- 
CD8 mAb, the serum levels of specific cytotoxic alloantibody in graft recipient 
serum were measured by ^ C r  release from labelled lymphoblasts, in the presence 
of guinea pig complement. The results are shown in Figure 5.3.
The results shown are of day 7 sera, in all groups. There was a consistently 
high level of specific alloantibody production in the unmodified group of animals, 
all of whom rejected their grafts with first set kinetics. Similarly, there was a high 
level of alloantibody in the sera of those animals which had been treated with anti- 
CD8 mAb and had rejected their grafts in the proven absence of CD8+ CTLs. In 
complete contrast, however, in those animals who had been treated with anti-CD4 
mAb, and had not acutely rejected their grafts, it was found that the specific 
cytotoxic alloantibody response had been completely abrogated.
This interesting finding tends to suggest that specific alloantibody may 
well be acting as the crucial effector mechanism in the rejection of the class I 
disparate cardiac allograft in this rat model, as those animals in which prolonged 
graft survival was achieved were those in which the alloantibody production had 
been prevented.
The combination of the fact that anti-CD4 treatment resulted in prolonged 
graft survival, and that the alloantibody response was completely abrogated, 
suggest that the fact that CD4+ cells were not completely depleted (as shown by 
FACS analysis) is not of great significance, and the likelihood is that the mAb 
treatment has functionally, if not numerically, depleted the CD4+ T cell 
population.
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Figure 5.3 The effect of in vivo monoclonal 
antibody treatment on cytotoxic alloantibody 
response (day 7) to a c la ss  I disparate graft.
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* RT1 u sera  were assayed  for specific cytotoxicity against 51 Cr labelled 
R8 lymphoblasts in the p resense  of guinea pig complement.
** Depletion of CD4+ cells by mAb has eliminated the specific
cytotoxic alloantibody response against a class I disparate heart graft.
5:5 Restoration of rejection by serum transfer.
To further the hypothesis, that specific alloantibody effects the acute 
rejection of a cardiac allograft, it was decided to see whether it was possible to 
restore the ability to reject such a graft to an animal which would not normally do 
so, by the administration of immune serum.
To this end, a group of 9 RTlu rats were transplanted. Five of these 
received an R8 cardiac graft and the other 4 an RTlc heart. As before, they were 
all treated with the anti-CD4 mAbs 0X35 & 0X38 from the day of 
transplantation.
These animals were then given three intravenous injections of day 10 
rejecting serum, on days 3,4 & 5 post-transplant. This time scale was chosen to 
mimic the appearance of specific alloantibody in the serum of an unmodified 
rejecting animal which occurs from day 3 onwards. The day 10 rejecting serum 
was obtained by pooling the sera from several RTlu rats which had rejected R8 
hearts and were sacrificed on day 10 post-transplant. The serum was heat 
inactivated in a water bath at 56°C for 30 minutes and then stored at minus 21°C 
until required. The effect of the passive transfer of this immune serum is 
represented in Figure 5.4.
It was found that those animals which had received an RTlc heart, anti- 
CD4 treatment, and had then been reconstituted with the rejecting serum, all had 
significant prolongation of graft survival time (33,36,>175,>175 days), as had 
been seen with anti-CD4 treatment alone (12,14,34,57,73,>200,>200,>200). In 
striking contrast, however, those animals which had been given R8 hearts and 
treatment with anti-CD4 mAb and had then been reconstituted with day 10 
rejecting serum (raised against an R8 graft), all rejected their allografts with first- 
set kinetics (5,6,6,7 & 7 days) [p=0.004, Mann-Whitney].
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Figure 5.4 Ability of passively transferred 
immune serum to restore rejection 
in anti-CD4 treated recipients.
Specificity control (n=4) 
RT1c-^RT1u + immune serum
100
80 -
60 -
A--------------
A-!-
No serum  (n=8) 
R8-^RT1u
-A >
40 -
20 -
immune serum  (n=5) 
R8—*RT1 u
20 40 60
Days after transplant
80
** Treatment with three intra-venous injections of immune serum on 
days 3,4 & 5 post-transplant completely restored the ability of a 
anti-CD4 treated animal to specifically reject an R8 heart graft.
*** p=0.004
The conclusion to be taken from these results is that passive transfer of 
immune serum is sufficient to restore rejection to an anti-CD4 mAb treated 
animal.
5:6 Conclusions from anti-CD4 mAb experiments.
In the previous chapter it was shown that this particular class I disparate 
allograft was being acutely rejected without any significant contribution from 
CD8+ cytotoxic T cells. This work has been expanded to examine the role of the 
CD4+ T cell and it has been shown that partial numerical depletion of these cells, 
by in vivo administration of 0X35 & 0X38 monoclonal antibodies, results in 
prolonged graft survival, and that this failure to reject the allograft correlated with 
a failure to produce the specific cytotoxic alloantibody response seen in 
unmodified, and in anti-CD8 treated, animals.
Shizuru et al published similar findings when they examined the effect of 
pre-transplant treatment with 0X38 alone, on the survival of fully MHC disparate 
heart grafts in the rat. Following pre-treatment of the rat, which ended on the day 
of transplantation, all rats treated with 0X38 had prolonged survival of their grafts 
for >175 days. In addition they reported that rats treated in this way failed to 
develop an antibody reaction against the 0X38 mAb itself. They went on to give a 
second heart graft to those anti-CD4 treated animals which had not rejected their 
first grafts and found that these animals showed donor-specific unresponsiveness 
to the second graft, but not to a third party graft which was rejected rapidly. This 
effect even persisted when the second graft was given >90 days following 
removal of the first graft, during which time the recipient was without any 
alloantigenic stimulation, and they conclude that the anti-CD4 pre-treatment
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depletes thymically processed, alloantigen specific, CD4+ T cells and that new 
emerging thymic migrants are rendered unresponsive or anergic following 
encounter with the alloantigen (Shizuru, Seydel, Flavin et al, 1990).
Finally, it has been convincingly demonstrated that the passive transfer of 
immune serum can specifically restore rejection to an anti-CD4 treated animal.
The conclusion from the above is that it is the CD4+ T cell which is 
crucial to the regulation of the rejection of this class I disparate cardiac allograft 
and that it is sufficient, with or without the presence of CD8+ T cells, to mediate 
rejection in this model.
Furthermore, the results of this work suggest that the CD4+ T cell is acting 
by providing cytokine "help" for the production of specific, cytotoxic alloantibody 
against the transplanted graft.
The question remains, however, whether this specific alloantibody is the 
true effector mechanism of the rejection response, presumably by mediating 
complement dependent cytotoxicity (CDC), or whether it simply produces its 
effect by interactions with cellular effector components by way of an antibody 
dependent cellular cytotoxicity reaction (ADCC). Earlier observations in this 
laboratory, that graft infiltrating cells in class I disparate kidney allografts, both 
rejecting and not rejecting, lacked any donor-specific cytotoxicity, but that the 
rejecting animal generated high levels of donor-specific alloantibody, stimulated 
the interest in alloantibody as a potential effector mechanism in acute allograft 
rejection (Gracie et al, 1990). In this more recent work with the cardiac graft 
model, it has been possible to demonstrate the ability of rejecting serum to cause 
lysis, in vitro, of cultured layers of donor strain, cardiac endothelial cells, by CDC 
as described in Chapter 3 (3:3). In this experiment the recipient rats own serum 
was the only source of complement. To extend this work to the in vivo animal
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model it was decided to examine the effect of complement depletion of the 
recipient, on the ability to restore rejection to an anti-CD4 treated animal by 
passive transfer of heat-inactivated, day 10 rejecting serum. Without complement 
depletion such an animal will reject its graft acutely and i f , as we are suggesting, 
the effector mechanism is CDC following activation by alloantibody, it might be 
expected that complement depletion would result in prolonged graft survival, in 
this model.
As a means of depleting serum complement in the graft recipients 
intramuscular injections of cobra venom factor (CoVF) were used, which results 
in a significant, but transient, reduction of complement activity through 
inactivation of C3, and subsequent complement components. Multiple injections 
of CoVF produce a prolonged depletion of C3, but after about 6 days of treatment 
the C3 inactivator complex is eliminated more rapidly than before, as a result of 
an immune response against the CoVF itself (Cochrane, Muller-Eberhard & 
Aikin, 1970). Treatment with CoVF has been shown to abrogate hyperacute 
rejection of cardiac allografts in rats (Whittum & Lindquist, 1977; Forbes, Pinto- 
Blonde & Guttmann, 1978), and Forbes et al also demonstrated that the usual 
morphological features of hyperacute rejection, namely, platelet aggregation, 
intravascular fibrin, endothelial destruction, neutrophil infiltration, and 
myocardial necrosis were absent in those animals whose complement was 
depleted prior to transplantation. They also found that rat C3 could not be detected 
bound to the allograft, although IgG was frequently detected, and they concluded 
that complement activation by graft-bound alloantibody was a critical effector 
mechanism of hyperacute rejection in that particular model.
There is little similar published work concerning acute allograft rejection, 
however, where the role of alloantibody is much less generally accepted.
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5:7 Complement depletion by cobra venom factor.
Earlier in this thesis it has been shown that, in the strain combination of R8 
to RTlu, an RTlu recipient of an R8 heart which has been treated with anti-CD4 
mAbs, will not reject that heart graft. In addition, it has been demonstrated that 
passive transfer of day 10 rejecting serum to such animals completely restores 
their ability to reject such a graft, with similar kinetics to those of an unmodified, 
acute rejection.
It was next decided to test the hypothesis that alloantibody was initiating 
the rejection response in these animals by CDC.
To this end, four RTlu recipients were pre-treated, on the day prior to 
transplantation, with a 0.2ml, intramuscular injection of cobra venom factor, and 
this was repeated every second day, up to and including day 10 post-operatively. 
Figure 5.5 shows the effect on serum complement levels in the RTlu rat of this 
CoVF regime.
On the day after the first dose of CoVF the RTlu rats were given an R8 
heart graft and were started on the usual anti-CD4 treatment regime. Each rat was 
then given 3 consecutive, daily intravenous injections of 1ml of day 10 rejecting 
serum, and the hearts were monitored in the usual fashion, by daily palpation 
through the abdominal wall.
The finding was of a short, but statistically significant, increase in the graft 
survival time in the CoVF treated group (p=0.017). Following depletion of serum 
complement, the mean graft survival time in those animals reconstituted with 
rejecting serum was 11.2 days (11,11,11,12), compared with a mean graft survival 
time of 6.2 days (5,6,6,7,7) in those animals with an intact complement system 
(Figure 5.6). This result suggests that the detrimental effect of the passively
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transferred rejecting serum is, indeed, as a result of alloantibody mediated CDC, 
as it is prevented, albeit temporarily, by the depletion of serum complement. A 
likely explanation for the fact that rejection is restored around day 11 or 12 is that 
administration of CoVF becomes ineffective in depleting serum complement as it 
is known that an immune response is mounted against the CoVF-C3 complex after 
about 6 days of administration and it becomes progressively more difficult to 
maintain complement depletion with repeated injections of CoVF (Cochrane et al, 
1970). It would be of interest, to complete the picture, to know what the effect of 
treating with anti-CD4 mAb and CoVF would be, without the addition of the 
rejecting serum. This experiment has not been performed.
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CHAPTER 6 
General Summary, Conclusions and Discussion.
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6:1 The need for further study of allograft rejection.
The aim of this thesis has been to examine the cellular and humoral events 
taking place, in vivo, in the rejection of a cardiac allograft in the rat
The work has been undertaken with a view to increasing our understanding 
of the complex interactions at play in acute allograft rejection, which remains the 
greatest, and most commonly encountered challenge in clinical transplantation. 
The "pot of gold" at the end of this particular rainbow is the development of a 
highly specific, and hopefully much less toxic, form of immunosuppression as a 
result of targeting those effector mechanisms which we know to be crucial in any 
one rejection response.
Over recent years, research into the mechanisms of allograft rejection has 
resulted in the introduction of increasingly effective treatment regimens for the 
prevention of organ graft rejection, such as cyclosporin, FK506 and OKT3, but it 
remains the case that all of the current forms of immunosuppression are associated 
with significant, and in some cases life-threatening, side-effects. Given the 
chronic shortage of all types of human organs for transplantation, and the ever- 
spiralling cost of long-term hospital and community support for patients with end- 
stage organ failure, of whatever type (Green, 1988), it is imperative that those 
organs which are made available for transplant should have the best possible 
chance of long-term survival in their recipient.
This clinical end-point validates the continuing experimental search to 
elucidate the cause of acute allograft rejection.
As has been explained earlier in this thesis, the fact that all clinical 
transplant recipients are receiving immunosuppression to prevent the rejection of 
their grafts makes it impossible to study the mechanisms of unmodified allograft
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rejection in the human model. Fortunately, there are considerable similarities in 
the immune response to an allograft in different species and it is therefore in 
animal models of acute rejection that the bulk of current research in this field is 
taking place.
As a result of previous work in this laboratory (Gracie et al, 1990), which 
challenged the widely held concept of a crucial role for the CD8+ CTL in the 
rejection of an isolated class I MHC disparate graft (Lowry et al, 1985), and 
which suggested a possible role for alloantibody in the rejection of a class I 
disparate renal allograft, it was decided to investigate the effector mechanisms in 
the rejection of an isolated class I MHC disparate, heterotopic, cardiac allograft in 
the rat.
6:2 Allorecognition.
The MHC restrictions of CD4+ and CD8+ T cells, which recognise class II 
and class I MHC respectively, are generally accepted.
As such, it was surprising to find, in both renal and cardiac transplantation 
between rat strains differing only at the classical class I locus, that the graft was 
being rejected in the complete absence of CD8+ CTLs, as conventional thinking 
on antigen presentation and recognition would have it that the foreign, or non-self, 
class I MHC could only be detected by CD8+ T cells. One would, therefore, have 
expected that removal of these effector cells would result in the long-term survival 
of such a graft. That this was not the case, in this experimental model, suggests 
one of two possibilities:
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1) The depletion of CD8+ T cells, by the mAb 0X8, has not been 
complete, and there are some CD8+ cells remaining which are able 
to recognise the class I disparity of the transplanted allograft, and 
to subsequently mount a response against it.
This work has shown, by the combination of immunohistology, two-colour 
FACS analysis and in vitro cytotoxicity assays, that treatment with MRC 0X8, in 
this rat model, has resulted in complete elimination, both phenotypically and 
functionally, of CD8+ T cells and it can be confidently stated that these class I 
disparate grafts are being rejected in the absence of CD8+ cells.
It has recently been suggested that the mAb treatment, itself, activates a 
unique population of CD8+, OX8-resistant CTL precursors which, with the 
assistance of Tj_j cells and in the presence of some non-MHC, minor antigen mis­
match, are responsible for the rejection of a class I disparate skin graft in mice 
(Rosenberg et al, 1991). In the model of rat heart allograft used in this thesis 
however, no such cells were found and no CTL activity could be demonstrated, 
but it is true to say that the donor and recipients were fully matched for minor 
antigens, which Rosenberg implies would prevent the activation of the precursor 
cells by the anti-CD8 mAb. This is an area which requires closer inspection before 
any valid conclusions can be drawn.
2) CD8+ T cells are not required for the recognition and rejection 
of a class I disparate graft.
If this hypothesis is to be believed, some alternative to the accepted 
mechanisms of MHC recognition and allograft rejection must be proposed.
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Conventional thinking regarding allorecognition believes that the direct 
recognition of foreign MHC antigens by the TCR results in the activation and 
proliferation of T lymphocytes, as seen in the mixed lymphocyte reaction, in vitro 
(Bach & Hirschom, 1964).
As was mentioned briefly in chapter 4, there is increasing evidence to 
support the interesting concept of an "indirect pathway" of alloantigen recognition 
by T cells (Rock et al, 1983; Golding & Singer, 1984; Cheng et al, 1990; Lechler 
et al, 1990). By this mechanism it is suggested that MHC class I antigens can be 
processed by antigen presenting cells and that peptide fragments derived from the 
allogeneic MHC may then be presented to CD4+ T cells in the protein 
presentation groove of self, MHC class II molecules. It has recently been 
convincingly demonstrated by Dalchau and co-workers that the injection of 
purified peptide fragments of MHC molecules, derived from a DA rat, into an 
allogeneic Lewis recipient results in the production of alloantibodies against the 
peptide fragments (but not the intact MHC), suggesting that indirect recognition 
had occurred. When these immunised Lewis rats were subsequently given a DA 
skin graft it was rejected in accelerated fashion. The authors conclude that indirect 
allorecognition can play an important role in the effector mechanisms of allograft 
rejection especially in the priming of Tjj cells (Dalchau, Fangmann & Fabre, 
1992; Fangmann, Dalchau & Fabre, 1992).
This alternative theory of antigen presentation and recognition is appealing 
as an explanation of how a class I disparate graft, such as has been studied in this 
thesis, can be recognised as foreign by a recipient which is completely devoid of 
CD8+ T cells.
It is our contention that MHC class I molecules are shed from the graft in 
large quantities following transplantation, and that this antigenic material is then
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processed, by APCs centrally in the graft recipient, and is then presented as 
peptide fragments, to the recipient's CD4+ T cells in the groove of self, class II 
MHC molecules. The result of this process will be the activation of the CD4+ T 
cells and, by the release of various cytokines, the initiation of the effector 
mechanisms leading to the specific rejection of the graft.
Alternatively, it has also been proposed that the activation of the CD4+ T 
cells may occur in the graft itself, following recognition of MHC disparities as 
presented by APCs of donor origin. The initial argument against such a 
possibility, in our class I disparate, CD8+ T cell depleted model, was the belief 
that class II MHC molecules always presented peptides derived from the 
degradation of exogenously derived proteins, and would therefore, in this model, 
be identical to recipient class II MHC, and would not be perceived as foreign by 
the recipient CD4+ T cells.
It has now been demonstrated, however, that peptides derived from 
endogenously synthesized proteins may be presented by class II MHC molecules 
(Jin, Shih, Berkower, 1988; Jacobson, Sekaly, Jacobson et al, 1989), and, 
moreover, that endogenous peptide derived from self class I MHC may be 
presented in the peptide binding groove of self class II MHC molecules (Chen et 
al, 1990).
It is conceivable, therefore, that CD4+ T cells could be activated locally, 
within the graft, by recognition of donor class I MHC peptide fragments being 
presented in the groove of donor class II MHC molecules, on the surface of donor 
APCs.
The more conventional theory of central activation, in draining lymph 
nodes or recipient spleen, following antigen processing and presentation by 
recipient APCs remains, in my view, the more plausible.
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Whether the CD4+ T cell activation takes place in the recipient lymphoid 
system or within the graft itself, the concept of an indirect pathway of antigen 
recognition, as outlined above, could account for the finding of the recognition of 
a class I MHC disparate allograft as foreign by a recipient devoid of CD8+ T 
cells. It does not, however, give us any information as to the effector mechanisms 
which bring about the subsequent destruction of the allograft, other than that they 
are initiated by the influence of activated CD4+ T cells, and that CD8+ T cells are 
not required.
6:3 Effector mechanisms of acute allograft rejection.
Whatever the final pathway of acute allograft rejection might be, it is 
widely recognised that the CD4+ T cell plays a crucial role in recruiting, and 
directing the different arms of the immune response against an allograft 
(Steinmuller, 1985; Mason & Morris, 1986; Hall, 1991). This control is mediated 
by the release of various lymphokines by the CD4+ T cell. The number and nature 
of these molecules, and their effects on cellular and humoral components of the 
immune response, are currently the subject of intense research, in the field of 
prevention of allograft rejection, as new techniques for their identification and 
assessment, such as polymerase chain reaction (PCR) and in situ hybridization, 
are developed.
Other than to acknowledge the importance of these molecules as a product 
of activated T cells, no further attempt to explore their role in allograft rejection 
has been made in this thesis, which has concentrated on the effector mechanisms 
which bring about the destruction of a rejected graft, albeit as a result of cytokine 
release by activated CD4+ T cells.
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As has already been stated, the demonstration of the rejection of a class I 
MHC disparate graft in an animal devoid of CD8+ cells has called into question 
the belief that the CD8+ CTL was essential in this system (Lowry et al, 1985).
We have consistently shown that such a graft can be acutely rejected in the 
complete absence of CD8+ T cells, following in vivo depletion of such cells by 
mouse anti-rat monoclonal antibodies.
Subsequently, it has been demonstrated that similar depletion of CD4+ T 
cells, by in vivo administration of anti-CD4 monoclonal antibodies, resulted in the 
long-term survival of a class I disparate graft, despite the continuing presence of 
CD8+ T cells in the graft recipients.
The conclusion from this work is that the CD4+ T cell is, indeed, crucial in 
the initiation of the acute rejection response, in this model, but the CD8+ T cell is 
not required.
It is important, however, not to completely disregard the CD8+ T cell, as it 
was also found that when the allograft recipient is treated with both anti-CD4 and 
anti-CD8 mAbs, the heart grafts were rejected with first-set kinetics, in the 
absence of an alloantibody response. This finding may suggest that CD8+ cells 
may have a suppressor effect on those CD4+ cells which remain following 
depletion with 0X35/0X38 mAb treatment, and that removal of these cells by 
0X8 mAb therapy allows the remaining CD4+ T cells to initiate an effective 
cellular rejection response.
What, then, is the effector mechanism of the rejection response which 
results in the destruction of a class I disparate heart graft, following the depletion 
of CD8+ T cells, and which is abrogated by the depletion of CD4+ T cells by anti- 
CD4 mAb treatment?
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The various types of immune responses which may, individually or 
collectively, be implicated in allograft rejection were summarised in Chapter 1 of 
this thesis (1:9.3).
Influenced by previous work in this laboratory (Grade et al, 1990), which 
demonstrated a strong, specific alloantibody response against a class I disparate 
renal allograft, the concept of alloantibody as an effector mechanism of acute 
allograft rejection has been pursued further.
As with the renal allograft model (and using the same rat strain 
combinations), we found that both unmodified heart graft rejection, and rejection 
following CD8+ cell depletion, occurred in the presence of a pronounced, and 
specific, alloantibody response. In the subsequent experiments involving depletion 
of CD4+ T cells, with resulting long-term graft survival, the specific alloantibody 
response had been prevented. It, therefore, seemed an attractive prospect that the 
alloantibody had been the effector mechanism responsible for the rejection of the 
grafts in the anti-CD8 treated animals. Were this to be the case, the passive 
transfer of specific, hyperimmune serum, to a graft recipient which has been 
treated with anti-CD4 mAb, should restore that animals' ability to reject its class I 
disparate graft. This was, indeed, the finding of the experiment detailed in Chapter 
5 (5:5), where passive transfer of hyperimmune serum, given intravenously on 
days 3,4 & 5 post-transplant, resulted in the restoration of first-set graft rejection 
to a CD4+ T cell, depleted group of rats.
It has previously been shown that a rat cardiac allograft can be acutely 
rejected in the absence of an alloantibody response (Lowry & Forbes, 1984), and 
this is in keeping with our finding of graft rejection in those animals which had 
been treated with both anti-CD4 and anti-CD8 mAbs and which had no 
demonstrable alloantibody present at the time of rejection, but it cannot be
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concluded from this that alloantibody is incapable of producing rejection in 
different circumstances. The fact that administration of hyperimmune serum is 
able to restore rejection to an animal which will otherwise not reject a heart graft, 
and which has had its alloantibody production prevented, is strong evidence to 
suggest that specific alloantibody has the ability to act as an effector of acute 
rejection, in this particular model of a cardiac allograft with a class I MHC 
antigen disparity.
6:4 Mechanism of tissue destruction.
The ideal form of effective immunosuppression should intervene in the 
immune response to prevent any form of tissue damage from occurring in the 
graft.
In order to establish whether a cellular or a humoral phenomenon is a 
potential effector mechanism of rejection, it is essential to demonstrate its' 
capacity to cause actual cellular damage to cell types found within the graft. The 
various types of known immunological injury were summarised in Chapter 1 of 
this work, and include: cytotoxic T cells; delayed-type hypersensitivity reaction; 
antibody dependent, cellular cytotoxicity & antibody mediated, complement 
dependent cytotoxicity.
The conclusion of this thesis, that alloantibody is capable of acting as the 
effector mechanism in the rejection of a class I disparate cardiac allograft, is 
strengthened by the demonstration of the ability of immune serum to specifically 
lyse neonatal cardiac endothelial cells, of donor origin, cultured in vitro. This cell 
destruction can only be as a result of complement dependent cytotoxicity. In 
addition, it has been shown here that depletion of serum complement in vivo, by 
intramuscular injections of cobra venom factor, is capable of delaying the
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rejection of a graft by a CD4+ T cell depleted animal which has been reconstituted 
with day 10 rejecting serum, supporting the argument that alloantibody is causing 
rejection by mediating a complement-dependent cytotoxic reaction.
6:5 Conclusion
It is not my contention that alloantibody, alone, should be put forward as 
the major effector mechanism in acute allograft rejection, but rather that it should 
be recognised as a potentially important effector in this type of graft rejection. 
This has not been the case up until now, as it has generally been accepted that the 
importance of alloantibody lies in the, relatively uncommon, clinical situation of 
hyperacute rejection, where pre-existing alloantibody causes the immediate 
rejection of a vascularised allograft.
If specific antibody, produced as a result of exposure to foreign MHC 
antigens, following allograft transplantation, is capable of causing the acute 
rejection of that graft then it presents another possible target for specific 
immunosuppression therapies, with potential therapeutic applications.
Whilst it is true that the results described in this thesis were produced in a 
very highly controlled, and artificial environment, it is becoming ever-more 
apparent that the rejection of an allograft is a multi-factorial phenomenon, 
involving many potential effector mechanisms with the ability to adapt their 
response to deal with whatever challenge they are presented with.
The CD4+ T cell is increasingly seen as the linch-pin upon which the 
entire process of graft rejection depends.
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